Tokushima University / Educator and Researcher Directory --- Niimura, Takahiro

Personal Web Page

https://orcid.org/0000-0003-2033-4246 (ORCID)

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Naoto Okada, Hirofumi Hamano, Kenta Yagi, Takahiro Niimura, Fuka Aizawa, Mitsuhiro Goda, Yoshito Zamami, Takashi Kitahara and Keisuke Ishizawa : Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database., International journal of clinical pharmacology and therapeutics, Vol.62, No.2, 69-76, 2024. (Summary) Although further analyses are required to confirm our findings, this study indicated that pre-treatment with EGFR-TKI might not increase the ILD risk after ICI treatment. (Keyword) Humans / Lung Neoplasms / Immune Checkpoint Inhibitors / Carcinoma, Non-Small-Cell Lung / Retrospective Studies / Japan / Lung Diseases, Interstitial / ErbB Receptors / Protein Kinase Inhibitors (Link to Publication Site) ● Publication site (DOI): 10.5414/CP204491 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37969096 ● Search Scopus @ Elsevier (PMID): 37969096 ● Search Scopus @ Elsevier (DOI): 10.5414/CP204491 (DOI: 10.5414/CP204491, PubMed: 37969096)
2.	Toshihiro Koyama, Shunya Iinuma, Michio Yamamoto, Takahiro Niimura, Yuka Osaki, Sayoko Nishimura, Ko Harada, Yoshito Zamami and Hideharu Hagiya : International Trends in Adverse Drug Event-Related Mortality from 2001 to 2019: An Analysis of the World Health Organization Mortality Database from 54 Countries., Drug Safety, Vol.47, No.3, 237-249, 2023. (Summary) The burden of ADEs has increased internationally with rising mortality rates. Establishing pharmacovigilance systems can facilitate efforts to reduce ADE-related mortality rates globally. (Keyword) male / Humans / female / World Health Organization / Europe / public health / Databases, Factual / Drug-Related Side Effects and Adverse Reactions / Mortality / Global Health (Link to Publication Site) ● Publication site (DOI): 10.1007/s40264-023-01387-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38133735 ● Search Scopus @ Elsevier (PMID): 38133735 ● Search Scopus @ Elsevier (DOI): 10.1007/s40264-023-01387-0 (DOI: 10.1007/s40264-023-01387-0, PubMed: 38133735)
3.	Kaito Tsujinaka, Yuki Izawa-Ishizawa, Koji Miyata, Toshihiko Yoshioka, Kohei Oomine, Honoka Nishi, Masateru Kondo, Syuto Itokazu, Tatsumi Miyata, Takahiro Niimura, Maki Sato, Fuka Aizawa, Kenta Yagi, Masayuki Chuma, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection., Biomedicine & Pharmacotherapy, Vol.167, 2023. (Summary) Aortic dissection is an adverse event of angiogenesis inhibitors; however, the association between the drugs and aortic dissection is unclear. Therefore, we investigated if and how angiogenesis inhibitors increase the onset of aortic dissection using pharmacologically-induced aortic dissection-prone model (LAB) mice, cultured endothelial cells, and real-world databases, which is a novel integrated research approach. Disproportionality analysis was performed and calculated using the reporting odds ratio as a risk signal using a worldwide database of spontaneous adverse events to estimate the risk of adverse events. Angiogenesis inhibitors, but not other hypertension-inducing drugs, showed significant risk signals for aortic aneurysms and dissection. A retrospective cohort analysis using JMDC, a medical receipt database in Japan, showed that the history of atherosclerosis and dyslipidemia, but not hypertension, were significantly associated with the onset of aortic dissection during angiogenesis inhibitor medication administration. For in vivo studies, sunitinib (100 mg/kg/day) was administered to LAB mice. Sunitinib increased systolic blood pressure (182 mmHg vs. 288 mmHg with sunitinib; p<0.01) and the incidence of aortic dissection (40% vs. 59% with sunitinib; p = 0.34) in mice. In vivo and in vitro studies revealed that sunitinib increased endothelin-1 expression and induced endothelial cell damage evaluated by intracellular- and vascular cell adhesion molecule-1 expressions. The increased risk of developing aortic dissection with angiogenesis inhibitors is associated with the development of drug-specific hypertension via endothelial cell damage and endothelin-1 expression. Our findings are invaluable in establishing safer anticancer therapies and strategies to prevent the development of vascular toxicity in high-risk patients. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.biopha.2023.115504 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37722188 ● Search Scopus @ Elsevier (PMID): 37722188 ● Search Scopus @ Elsevier (DOI): 10.1016/j.biopha.2023.115504 (DOI: 10.1016/j.biopha.2023.115504, PubMed: 37722188)
4.	Mami Neishi, Hirofumi Hamano, Takahiro Niimura, Masaya Denda, Kenta Yagi, Koji Miyata, Tsung-Jen Lin, Tsukasa Higashionna, Mitsuhiro Goda, Yoshito Zamami, Keisuke Ishizawa and Hideki Nawa : Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases, Toxicology and Applied Pharmacology, Vol.475, 116632, 2023. (Summary) It is unclear whether the s (-) form of esomeprazole (EPZ) has an improved safety profile when compared with its racemic form omeprazole (OPZ). We assessed the potential complications of these optical isomers when combined with cilostazol, clopidogrel, and prasugrel, which are frequently used concomitant medications. Using two adverse event spontaneous reporting databases, Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS), adverse event names for hemorrhage, venous/arterial embolization, and thrombus were obtained from the Medical Dictionary for Regulatory Activities. Reported odds ratios were calculated using a 2 × 2 contingency table, and a signal was considered present if the lower limit of the 95% confidence interval was >1. In combination with cilostazol, a hemorrhagic signal for OPZ in JADER and arterial emboli and thrombus signals for EPZ were detected in both databases. In combination with clopidogrel, OPZ showed arterial emboli and thrombus signals in JADER and venous/arterial emboli and thrombus signals in FAERS, while EPZ displayed arterial emboli and thrombus signals in FAERS. In contrast, when in combination with prasugrel, there were no adverse event signals in either database. This study has confirmed using big data, that EPZ, the optical isomer and racemic form of omeprazole, has the beneficial characteristics of being less sensitive to CYP, as was intended by its design. (Keyword) Humans / United States / Esomeprazole / Omeprazole / Clopidogrel / Prasugrel Hydrochloride / Cilostazol / Adverse Drug Reaction Reporting Systems / Hemorrhage / Drug-Related Side Effects and Adverse Reactions / Databases, Factual (Link to Publication Site) ● Publication site (DOI): 10.1016/j.taap.2023.116632 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37482254 ● Summary page in Scopus @ Elsevier: 2-s2.0-85165980754 (DOI: 10.1016/j.taap.2023.116632, PubMed: 37482254, Elsevier: Scopus)
5.	Naoto Okada, Takahiro Niimura, Atsuyuki Saisyo, Yoshitaka Kawaguchi, Keisuke Ishizawa and Takashi Kitahara : Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System., Open forum infectious diseases, Vol.10, No.8, 2023. (Summary) This study revealed that among the anti-MRSA agents, disproportionality in the occurrence of EP was observed only with DAP. Our results suggest that sex, age, and treatment duration may affect the occurrence of DAP-induced EP. Clinicians should exercise caution regarding EP during DAP administration. (Link to Publication Site) ● Publication site (DOI): 10.1093/ofid/ofad414 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37601729 ● Search Scopus @ Elsevier (PMID): 37601729 ● Search Scopus @ Elsevier (DOI): 10.1093/ofid/ofad414 (DOI: 10.1093/ofid/ofad414, PubMed: 37601729)
6.	Tsukasa Higashionna, Keisaku Harada, Akinari Maruo, Takahiro Niimura, Elizabeth Tan, Thi Quynh Vu, Takayoshi Kawabata, Soichiro Ushio, Hirofumi Hamano, Makoto Kajizono, Yoshito Zamami, Keisuke Ishizawa, Ko Harada, Shiro Hinotsu, R Mitsunobu Kano, Hideharu Hagiya and Toshihiro Koyama : Trends in Head and Neck Cancer Mortality from 1999 to 2019 in Japan: An Observational Analysis., Cancers, Vol.15, No.15, 2023. (Summary) = 156,742). HNC mortality trends were analysed using joinpoint regression models to estimate annual percentage change (APC) and average APC (AAPC). Among men, no significant change was observed in the age-adjusted death rate trend from 1999 to 2014; however, a marked decrease was observed from 2014 to 2019. No changing point was observed in women. Age-adjusted mortality rates continuously decreased over the 21-year period, with an AAPC of -0.7% in men and -0.6% in women. In conclusion, the overall trend in age-adjusted rates of HNC-associated deaths decreased, particularly among men, in the past 5 years. These results will contribute to the formulation of medical policies to develop targeted screening and prevention programmes for HNC in Japan and determine the direction of treatment strategies. (Tokushima University Institutional Repository) ● Metadata: 118887 (Link to Publication Site) ● Publication site (DOI): 10.3390/cancers15153786 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37568602 ● Search Scopus @ Elsevier (PMID): 37568602 ● Search Scopus @ Elsevier (DOI): 10.3390/cancers15153786 (Tokushima University Institutional Repository: 118887, DOI: 10.3390/cancers15153786, PubMed: 37568602)
7.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis., Respiratory Research, Vol.24, No.1, 2023. (Summary) These findings suggest that targeting PLK1 may be a novel therapeutic approach for pulmonary fibrosis by inhibiting lung fibroblast proliferation without affecting lung epithelial cells. In addition, while in silico screening is useful, it is essential to fully determine the biological activities of candidates by wet-lab validation studies. (Keyword) Mice / Animals / Drug Repositioning / Thiophenes / Benzimidazoles / Lung / Idiopathic Pulmonary Fibrosis / Fibroblasts / Bleomycin (Tokushima University Institutional Repository) ● Metadata: 119057 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12931-023-02446-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37269004 ● Search Scopus @ Elsevier (PMID): 37269004 ● Search Scopus @ Elsevier (DOI): 10.1186/s12931-023-02446-x (Tokushima University Institutional Repository: 119057, DOI: 10.1186/s12931-023-02446-x, PubMed: 37269004)
8.	Takahiro Niimura, Koji Miyata, Hirofumi Hamano, Yuuki Nounin, Hiroto Unten, Masaki Yoshino, Satoru Mitsuboshi, Fuka Aizawa, Kenta Yagi, Toshihiro Koyama, Mitsuhiro Goda, Yasunari Kanda, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)., Drug Safety, 2023. (Summary) Systematic evaluation of ALK inhibitor-associated adverse events revealed differences in the cardiotoxicity profiles among ALK inhibitors. Understanding the differences in the cardiovascular toxicity profile of each ALK inhibitor will contribute to safe drug therapy when switching between ALK inhibitors. (Link to Publication Site) ● Publication site (DOI): 10.1007/s40264-023-01300-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37106270 ● Search Scopus @ Elsevier (PMID): 37106270 ● Search Scopus @ Elsevier (DOI): 10.1007/s40264-023-01300-9 (DOI: 10.1007/s40264-023-01300-9, PubMed: 37106270)
9.	Satoru Mitsuboshi, Hirofumi Hamano, Yurika Kuniki, Takahiro Niimura, Masayuki Chuma, Soichiro Ushio, Tsung-Jen Lin, Jun Matsumoto, Tatsuaki Takeda, Makoto Kajizono, Yoshito Zamami and Keisuke Ishizawa : Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases., The Annals of Pharmacotherapy, 2023. (Summary) The data in 2 separate databases consistently suggest that PPIs may increase the risk of rhabdomyolysis. The evidence for this association should be assessed in further drug safety studies. (Link to Publication Site) ● Publication site (DOI): 10.1177/10600280231156270 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36847276 ● Search Scopus @ Elsevier (PMID): 36847276 ● Search Scopus @ Elsevier (DOI): 10.1177/10600280231156270 (DOI: 10.1177/10600280231156270, PubMed: 36847276)
10.	Kenta Yagi, Akinori Maruo, Shunsuke Ishida, Fuka Aizawa, Soichiro Ushio, Satoshi Sakaguchi, Makoto Kajizono, Takahiro Niimura, Mitsuhiro Goda, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study., Clinical and Experimental Medicine, 2023. (Summary) Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether the use of PPIs or vonoprazan in patients with cancer receiving bevacizumab affected the duration of bevacizumab treatment. This observational study was conducted at two national university hospitals in Japan and involved 222 patients using oral PPIs (N = 190) or vonoprazan (N = 32) at the start of bevacizumab treatment between January 2015 and December 2018. Patients who received only one course of bevacizumab were excluded. The primary endpoint was the duration of bevacizumab treatment. The duration of bevacizumab treatment varied significantly between the PPI and vonoprazan groups. For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (p < 0.05) and was longer in the vonoprazan group than in the PPI group. However, for colorectal cancer, the median duration of bevacizumab treatment was 147 days longer in the PPI group than in the vonoprazan group. Selection of appropriate gastric acid secretion inhibitors may improve the therapeutic efficacy of anti-VEGF drugs, including bevacizumab. Oestrogen is a key regulator of this effect and may be responsible for the varying association between PPI or vonoprazan administration and the difference in bevacizumab treatment duration between colon cancer and other cancer types. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10238-023-01008-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36738305 ● Search Scopus @ Elsevier (PMID): 36738305 ● Search Scopus @ Elsevier (DOI): 10.1007/s10238-023-01008-1 (DOI: 10.1007/s10238-023-01008-1, PubMed: 36738305)
11.	Takahiro Niimura, Yoshito Zamami, Koji Miyata, Takahisa Mikami, Mizuho Asada, Keijo Fukushima, Masaki Yoshino, Satoru Mitsuboshi, Naoto Okada, Hirofumi Hamano, Takumi Sakurada, Rie Matsuoka-Ando, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Masayuki Chuma, Toshihiro Koyama, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Hiromichi Fujino, Yoshihiro Yamanishi and Keisuke Ishizawa : Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System., Journal of Clinical Pharmacology, Vol.63, No.4, 473-479, 2022. (Summary) Myasthenia gravis (MG) is a rare but fatal adverse event of immune checkpoint inhibitors (ICIs). We assessed whether patient characteristics differed between those with ICI-related myasthenia gravis and those with idiopathic myasthenia gravis. Reports from the US Food and Drug Administration Adverse Event Reporting System were analyzed. Multivariate analyses were conducted to evaluate the associations between age, sex, and ICI treatment and the reporting rate of myasthenia gravis. Among 5 464 099 cases between 2011 and 2019, 53 447 were treated with ICIs. Myasthenia gravis was reported more often in ICI users. Multiple logistic regression analyses showed that the reporting rate of ICI-related myasthenia gravis did not differ significantly between men and women; however, it was higher in older people than in younger people (adjusted odds ratio, 2.4 [95%CI, 1.84-3.13]). We also investigated useful signs for the early detection of myositis and myocarditis, which are fatal when overlapping with ICI-related myasthenia gravis. Patients with elevated serum creatine kinase or troponin levels were more likely to have concurrent myositis and myocarditis. Unlike idiopathic myasthenia gravis, there was no sex difference in the development of ICI-related myasthenia gravis, which may be more common in older people. Considering the physiological muscle weakness that occurs in the elderly, it may be necessary to monitor ICI-related myasthenia gravis more closely in older people. (Keyword) Male / United States / Humans / Female / Aged / Immune Checkpoint Inhibitors / United States Food and Drug Administration / Myocarditis / Myasthenia Gravis / Myositis (Link to Publication Site) ● Publication site (DOI): 10.1002/jcph.2187 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36453166 ● Search Scopus @ Elsevier (PMID): 36453166 ● Search Scopus @ Elsevier (DOI): 10.1002/jcph.2187 (DOI: 10.1002/jcph.2187, PubMed: 36453166)
12.	Rie Ando-Matsuoka, Kenta Yagi, Mayu Takaoka, Yuko Sakajiri, Tomokazu Shibata, Ryusuke Sawada, Akinori Maruo, Koji Miyata, Fuka Aizawa, Hirofumi Hamano, Takahiro Niimura, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Satoshi Sakaguchi, Yoshito Zamami, Yoshihiro Yamanishi and Keisuke Ishizawa : Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells., Drug Development Research, Vol.84, No.1, 75-83, 2022. (Summary) Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion, used as first-line agents in treating peptic ulcers. However, we have previously reported that PPIs may diminish the therapeutic effect of anti-vascular endothelial growth factor (VEGF) drugs in patients with cancer. In this study, we explored the effects of vonoprazan, a novel gastric acid secretion inhibitor used for the treatment of peptic ulcers, on the secretion of VEGF in cancer cells and attempted to propose it as an alternative PPI for cancer chemotherapy. The effects of PPI and vonoprazan on VEGF expression in cancer cells were compared by real-time reverse transcription-polymerase chain reaction and ELISA. The interaction of vonoprazan and PPIs with transcriptional regulators by docking simulation analysis. In various cancer cell lines, including the human colorectal cancer cell line (LS174T), PPI increased VEGF messenger RNA expression and VEGF protein secretion, while this effect was not observed with vonoprazan. Molecular docking simulation analysis showed that vonoprazan had a lower binding affinity for estrogen receptor alpha (ER-α), one of the transcriptional regulators of VEGF, compared to PPI. Although the PPI-induced increase in VEGF expression was counteracted by pharmacological ER-α inhibition, the effect of vonoprazan on VEGF expression was unchanged. Vonoprazan does not affect VEGF expression in cancer cells, which suggests that vonoprazan might be an alternative to PPIs, with no interference with the therapeutic effects of anti-VEGF cancer chemotherapy. (Keyword) Humans / Proton Pump Inhibitors / Endothelial Growth Factors / Molecular Docking Simulation / Peptic Ulcer / Pyrroles / Neoplasms (Tokushima University Institutional Repository) ● Metadata: 118289 (Link to Publication Site) ● Publication site (DOI): 10.1002/ddr.22013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36484282 ● Search Scopus @ Elsevier (PMID): 36484282 ● Search Scopus @ Elsevier (DOI): 10.1002/ddr.22013 (Tokushima University Institutional Repository: 118289, DOI: 10.1002/ddr.22013, PubMed: 36484282)
13.	Masayuki Chuma, Hirofumi Hamano, Takashi Bando, Masateru Kondo, Naoto Okada, Yuki Izumi, Shunsuke Ishida, Toshihiko Yoshioka, Mizuho Asada, Takahiro Niimura, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Sachiko Kasamo, Yuki Izawa-Ishizawa, Momoyo Azuma, Hiroaki Yanagawa, Yoshikazu Tasaki and Keisuke Ishizawa : Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real-world databases., Basic & Clinical Pharmacology & Toxicology, Vol.131, No.6, 525-535, 2022. (Summary) There has been growing concern in worsening survival and renal outcomes following vancomycin-associated nephrotoxicity (VAN) onset, but the factors associated with these phenomena remain unclear. To examine these factors, we performed a retrospective study combining the analysis of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was used to evaluate the relationship between VAN and mortality using odds ratios (ORs) and 95% confidence intervals (CIs). Next, electronic medical records (EMRs) were examined in a more robust cohort for evaluation of the association between renal outcomes and worsening survival using Cox proportional hazards regression models. FAERS analysis revealed a significant correlation between VAN occurrence and increased mortality (OR: 1.30; 95% CI: 1.17-1.46). EMR analysis showed that non-recovery of VAN was associated with increased hospital mortality (hazard ratio [HR]: 4.05; 95% CI: 2.42-6.77) and 1-year mortality (HR: 3.03, 95% CI: 1.98-4.64). The HR for VAN recovery was lower for patients with acute kidney injury (AKI) stage 2 (HR: 0.09; 95% CI: 0.02-0.40). Thus, worsening survival outcomes were associated with non-recovery of VAN, whereby AKI stage 2 was a significant risk factor. Progression to severe VAN should be prevented for better survival outcomes. (Keyword) Humans / Vancomycin / Retrospective Studies / Anti-Bacterial Agents / Acute Kidney Injury / Drug-Related Side Effects and Adverse Reactions / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.1111/bcpt.13799 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36169161 ● Search Scopus @ Elsevier (PMID): 36169161 ● Search Scopus @ Elsevier (DOI): 10.1111/bcpt.13799 (DOI: 10.1111/bcpt.13799, PubMed: 36169161)
14.	Hideki Nawa, Hirofumi Hamano, Takahiro Niimura, Koji Miyata, Kenta Yagi, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects., Clinical and Translational Science, Vol.15, No.12, 2982-2988, 2022. (Summary) Interstitial lung disease (ILD), as an adverse effect of certain drugs, leads to inflammation and damage in the walls of the alveoli, making it difficult for the alveoli to take up oxygen. Interstitial pneumonia with no identifiable cause is called idiopathic interstitial pneumonia (IIP), and, among the major IIPs, idiopathic pulmonary fibrosis (IPF) is diagnosed in about half of patients. Current treatment options are limited, among which the antifibrotic drugs nintedanib (Ofev) and pirfenidone (Pirespa) are the first-line drugs. In this study, we investigated the incidence of ILD possibly caused by antifibrotic agents using data from the Japanese Adverse Drug Event Report (JADER) database, a database of spontaneous adverse event reports published by the Pharmaceuticals and Medical Devices Agency (PMDA), and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), published by the FDA. We used the FAERS and JADER to detect the signals of adverse events on the basis of reporting odds ratios. The relationship between indications and adverse events was clarified by separating indications and adverse events using the spontaneous adverse event reporting database with novel drug involvement. Regarding the involvement of nintedanib and pirfenidone in the development of ILD, JADER and FAERS showed signals for both nintedanib and pirfenidone as suspect drugs, and no signals for nintedanib or pirfenidone as concomitant drug interactions were detected. We highlight this because there are only a few effective drugs for IPF, and effective and safe drug therapies should be implemented by taking into consideration drug-induced ILD. (Keyword) United States / Humans / Pharmaceutical Preparations / Drug-Related Side Effects and Adverse Reactions / Lung Diseases, Interstitial / Databases, Factual / Pyridones / United States Food and Drug Administration / Idiopathic Pulmonary Fibrosis (Tokushima University Institutional Repository) ● Metadata: 118179 (Link to Publication Site) ● Publication site (DOI): 10.1111/cts.13419 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36128688 ● Search Scopus @ Elsevier (PMID): 36128688 ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13419 (Tokushima University Institutional Repository: 118179, DOI: 10.1111/cts.13419, PubMed: 36128688)
15.	Shiori Nishiuchi, Kenta Yagi, Hiroumi Saito, Yoshito Zamami, Takahiro Niimura, Koji Miyata, Yoshika Sakamoto, Kimiko Fukunaga, Shunsuke Ishida, Hirofumi Hamano, Fuka Aizawa, Mitsuhiro Goda, Masayuki Chuma, Yuki Izawa-Ishizawa, Hideki Nawa, Hiroaki Yanagawa, Yasunari Kanda and Keisuke Ishizawa : Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis., European Journal of Pharmacology, Vol.928, No.175083, 2022. (Summary) These findings suggest that doxorubicin-induced cardiac events are suppressed by the administration of mosapride and sirolimus. (Keyword) Animals / apoptosis / Cardiotoxicity / data analysis / Doxorubicin / Mice / Myocytes, Cardiac / Pharmaceutical Preparations / RNA, Messenger / Sirolimus (Tokushima University Institutional Repository) ● Metadata: 117365 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2022.175083 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35659512 ● Search Scopus @ Elsevier (PMID): 35659512 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejphar.2022.175083 (Tokushima University Institutional Repository: 117365, DOI: 10.1016/j.ejphar.2022.175083, PubMed: 35659512)
16.	Masaya Kanda, Mitsuhiro Goda, Akiko Maegawa, Toshihiko Yoshioka, Ami Yoshida, Koji Miyata, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Takumi Sakurada, Masayuki Chuma, Kenta Yagi, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Yoshito Zamami and Keisuke Ishizawa : Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis., Clinical and Translational Science, Vol.15, No.7, 1664-1675, 2022. (Summary) Cisplatin is effective against many types of carcinoma. However, a high rate of renal damage is a clinical problem. Thus, there is a need to establish a method to prevent it. Although various compounds have been reported to be effective against cisplatin-induced renal injury, there are no examples of their clinical application. Therefore, we attempted to search for prophylactic agents with a high potential for clinical application. We used Cascade Eye to identify genes that are altered during cisplatin-induced renal injury, Library of Integrated Network-based Cellular Signatures (LINCS) to identify drugs that inhibit changes in gene expression, and a large database of spontaneous adverse drug reaction reports to identify drugs that could prevent cisplatin-induced kidney injury in clinical practice. In total, 10 candidate drugs were identified. Using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), we identified drugs that reduce cisplatin-induced kidney injury. Fenofibrate was selected as a candidate drug to prevent cisplatin-induced kidney injury based on the FAERS analysis. A model was used to evaluate the efficacy of fenofibrate against cisplatin-induced renal injury. Studies using HK2 cells and mouse models showed that fenofibrate significantly inhibited cisplatin-induced renal injury but did not inhibit the antitumor effect of cisplatin. Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin-induced renal injury. Analysis of data from multiple big databases will improve the search for novel prophylactic drugs with high clinical applicability. For the practical application of these findings, evaluation in prospective controlled trials is necessary. (Keyword) Acute Kidney Injury / Animals / Cisplatin / data analysis / Fenofibrate / kidney disease / Mice / Prospective Studies (Tokushima University Institutional Repository) ● Metadata: 117366 (Link to Publication Site) ● Publication site (DOI): 10.1111/cts.13282 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35445533 ● Search Scopus @ Elsevier (PMID): 35445533 ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13282 (Tokushima University Institutional Repository: 117366, DOI: 10.1111/cts.13282, PubMed: 35445533)
17.	Masayuki Chuma, Aki Nakamoto, Takashi Bando, Takahiro Niimura, Yutaka Kondo, Hirofumi Hamano, Naoto Okada, Mizuho Asada, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Toshihiko Yoshioka, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Yoshikazu Tasaki and Keisuke Ishizawa : Association between statin use and daptomycin-related musculoskeletal adverse events: A mixed approach combining a meta-analysis and a disproportionality analysis., Clinical Infectious Diseases, Vol.75, No.8, 1416-1422, 2022. (Summary) There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs. We used a mixed approach that combines two methodologies. First, we conducted a meta-analysis to examine the effects of statin use on DAP-related MAEs. Second, we conducted a disproportionality analysis using the FDA Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population. In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83, 95% confidence interval [CI]: 1.43-10.26) but not DAP-related myopathy (OR: 1.72, 95% CI: 0.95-3.12). In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69, 95% CI: 4.31-7.51) and rhabdomyolysis (ROR: 5.77, 95% CI: 4.33-7.68). Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis. The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety. (Tokushima University Institutional Repository) ● Metadata: 117810 (Link to Publication Site) ● Publication site (DOI): 10.1093/cid/ciac128 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35262686 ● Search Scopus @ Elsevier (PMID): 35262686 ● Search Scopus @ Elsevier (DOI): 10.1093/cid/ciac128 (Tokushima University Institutional Repository: 117810, DOI: 10.1093/cid/ciac128, PubMed: 35262686)
18.	Yoshito Zamami, Takahiro Niimura, Takehiro Kawashiri, Mitsuhiro Goda, Yutaro Naito, Keijo Fukushima, Soichiro Ushio, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Koji Miyata, Kenshi Takechi, Masayuki Chuma, Toshihiro Koyama, Daisuke Kobayashi, Takao Shimazoe, Hiromichi Fujino, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data., Biomedicine & Pharmacotherapy, Vol.148, 2022. (Summary) Thus, drug repositioning using data from large-scale basic and clinical databases enables the discovery of new indications for approved drugs with a high probability of success. (Keyword) Animals / Anticholesteremic Agents / Antineoplastic Agents / Big Data / Databases, Factual / Drug Repositioning / Humans / Hyperalgesia / Japan / Male / Mice / Mice, Inbred BALB C / Oxaliplatin / Peripheral Nervous System Diseases / Pre-Exposure Prophylaxis / Rats / Rats, Sprague-Dawley / Retrospective Studies / Simvastatin (Tokushima University Institutional Repository) ● Metadata: 117414 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.biopha.2022.112744 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35240525 ● Search Scopus @ Elsevier (PMID): 35240525 ● Search Scopus @ Elsevier (DOI): 10.1016/j.biopha.2022.112744 (Tokushima University Institutional Repository: 117414, DOI: 10.1016/j.biopha.2022.112744, PubMed: 35240525)
19.	Mami Uchida, Soichiro Ushio, Takahiro Niimura, Kenshi Takechi, Hitoshi Kawazoe, Noriaki Hidaka, Akihiro Tanaka, Hiroaki Araki, Yoshito Zamami, Keisuke Ishizawa, Yoshihisa Kitamura, Toshiaki Sendou, Hiromu Kawasaki, Hiroyuki Namba, Kazuhiko Shibata, Mamoru Tanaka and Shingo Takatori : Renin-Angiotensin-Aldosterone System Inhibitors Prevent the Onset of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Multicenter Study and in Vitro Evaluation., Biological & Pharmaceutical Bulletin, Vol.45, No.2, 226-234, 2021. (Summary) Oxaliplatin (OXA) is used in chemotherapy for various cancer types and is associated with acute and chronic neurotoxicity. However, a preventive strategy for OXA-induced peripheral neuropathy (OIPN) and its underlying mechanism remain unclear. We examined the effects of renin-angiotensin-aldosterone system inhibitors (RAASIs) on OIPN by performing a retrospective multicenter study and an in vitro assay. We retrospectively evaluated electronic medical records of 976 patients who underwent one or more courses of OXA-containing regimens at Ehime, Okayama, and Tokushima University Hospitals. The primary endpoint was the incidence of OIPN during or after OXA administration. The effects of RAASIs and OXA on the neurite length in PC12 cells were determined. The combined administration of an OXA-containing regimen and RAASI significantly inhibited the cumulative incidence grade-2 or higher OIPN (log-rank test; p = 0.0001). RAASIs markedly suppressed the development of both acute and chronic OIPN (multivariate analysis; p = 0.017 and p = 0.011). In an in vitro assay, 10 µM OXA suppressed the neurite length; treatment with 1 µM aliskiren, spironolactone, 10 µM candesartan, and enalapril significantly restored neurite length to the control level. Moreover, 1 µM SCH772984 (a selective inhibitor of extracellular signal-regulated kinase, ERK1/2) and 500 µM SQ22536 (a cell-permeable adenylate cyclase (AC) inhibitor) markedly abolished neurite-extending effects of candesartan and enalapril. These results indicate that RAASIs possess preventive or therapeutic effects in acute and chronic OIPN, candesartan and enalapril may increase in the activity of ERK1/2 and AC in PC12 cells. (Keyword) Angiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Animals / Antihypertensive Agents / Antineoplastic Agents / Calcium Channel Blockers / Female / Humans / Male / Neuroprotective Agents / Oxaliplatin / PC12 Cells / Peripheral Nervous System Diseases / Proportional Hazards Models / Rats / Renin-Angiotensin System / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b21-00852 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34803077 ● Search Scopus @ Elsevier (PMID): 34803077 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b21-00852 (DOI: 10.1248/bpb.b21-00852, PubMed: 34803077)
20.	Satoru Mitsuboshi, Takahiro Niimura, Masaya Kanda, Shunsuke Ishida, Yoshito Zamami and Keisuke Ishizawa : Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat., The Annals of Pharmacotherapy, Vol.56, No.8, 910-915, 2021. (Summary) The breast cancer resistance protein (BCRP) is a key drug transporter found in the liver, kidney, central nervous system, and gastrointestinal tract. Due to the wide expression of BCRP, interactions of other drugs with methotrexate (MTX) may differ in oral and intravenous MTX users, and understanding of these interactions may be useful in preventing severe adverse events. Febuxostat, a urate-lowering drug, inhibits BCRP. The objective of this study was to clarify the differences in the drug-drug interaction profiles of oral and intravenous methotrexate, associated with BCRP. We analyzed the Japanese Adverse Drug Event Report database and compared the frequency of hematologic events in patients taking oral and intravenous MTX, with or without the concomitant use of febuxostat or allopurinol. Hematologic events were defined as pancytopenia and neutropenia. Multiple logistic regression analysis was then used to identify the risk factors for hematologic events in oral and intravenous MTX users. We identified 8 453 oral and 810 intravenous MTX users with 546 and 126 cases of hematologic events, respectively. Compared with those not using febuxostat, a disproportionate number of hematologic events was observed in intravenous MTX users concomitantly using febuxostat ( < 0.01). The multivariate logistic analysis of intravenous MTX users showed that hematologic events were significantly associated with febuxostat use ( < 0.01) and age ≥ 60 years ( < 0.01). Our findings suggest that patients being treated with intravenous MTX who concomitantly use febuxostat may be at an increased risk of hematologic events, presumably due to BCRP-mediated drug-drug interaction. (Keyword) ATP Binding Cassette Transporter, Subfamily G, Member 2 / Allopurinol / Breast Neoplasms / Febuxostat / Female / Gout Suppressants / Humans / Methotrexate / Middle Aged / Neoplasm Proteins (Link to Publication Site) ● Publication site (DOI): 10.1177/10600280211055794 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34726078 ● Search Scopus @ Elsevier (PMID): 34726078 ● Search Scopus @ Elsevier (DOI): 10.1177/10600280211055794 (DOI: 10.1177/10600280211055794, PubMed: 34726078)
21.	Hideki Nawa, Takahiro Niimura, Hirofumi Hamano, Kenta Yagi, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects., Frontiers in Pharmacology, Vol.12, No.655605, 2021. (Summary) From 2002 to 2018, the number of patients with prostate cancer significantly increased from 679,023 to 1276,106 worldwide. Total prostatectomy (including robot-assisted prostatectomy), radiation therapy, and pharmacological treatment are commonly used to treat prostate cancer. The Chief of the Pharmaceutical Safety Division, that is, the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ), recently called for the revision of package inserts for ethical drugs. However, the pathogenesis of interstitial lung disease (ILD), a serious drug-induced adverse effect, remains unclear. Moreover, there have been no large-scale evaluations of potential complications associated with currently used antiandrogens, which are commonly employed to treat prostate cancer. Hence, ILD, as an adverse event, remains poorly understood. Therefore, we conducted a survey of reports in the Japanese Adverse Drug Event Report (JADER) database to investigate the potential association between the reporting of ILD and antiandrogen drug use in clinical practice. The occurrence of ILD was investigated by evaluating the relationship between antiandrogen drug use and ILD. Adverse event signals were detected with reporting odds ratios (RORs), using data from the JADER and FDA Adverse Event Reporting System (FAERS) databases, for the analysis of post-marketing adverse event reports. The JADER was used to examine the time profile of adverse event occurrence for each drug, whereas the FAERS was used to screen cases of unknown adverse events and analyze their trends of occurrence. The analysis of data from both databases revealed the 95% confidence interval lower limits of ROR for bicalutamide and flutamide to be > 1, and adverse event signals were detected following the use of either drug. While caution should be exercised for drugs that are new to the market, we conclude that drugs with similar therapeutic effects that have been in use for a long period should also be re-examined for potential adverse events. (Link to Publication Site) ● Publication site (DOI): 10.3389/fphar.2021.655605 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34177574 ● Search Scopus @ Elsevier (PMID): 34177574 ● Search Scopus @ Elsevier (DOI): 10.3389/fphar.2021.655605 (DOI: 10.3389/fphar.2021.655605, PubMed: 34177574)
22.	Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Ami Yoshida, Yoichi Murai, Yoshito Zamami, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Masayuki Chuma, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Effects of 5-HT₃ receptor antagonists on cisplatin-induced kidney injury., Clinical and Translational Science, 2021. (Summary) receptor antagonists do not worsen cisplatin-induced acute kidney injury. The findings should be validated in a prospective controlled trial before implementation in clinical practice. (Tokushima University Institutional Repository) ● Metadata: 116008 (Link to Publication Site) ● Publication site (DOI): 10.1111/cts.13045 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33982438 ● Search Scopus @ Elsevier (PMID): 33982438 ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13045 (Tokushima University Institutional Repository: 116008, DOI: 10.1111/cts.13045, PubMed: 33982438)
23.	Hideki Nawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments., Cancer Reports, 2021. (Summary) Treatment with abemaciclib and palbociclib is associated with a potential complication of interstitial lung disease, regardless of age. (Tokushima University Institutional Repository) ● Metadata: 116289 (Link to Publication Site) ● Publication site (DOI): 10.1002/cnr2.1402 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33939324 ● Search Scopus @ Elsevier (PMID): 33939324 ● Search Scopus @ Elsevier (DOI): 10.1002/cnr2.1402 (Tokushima University Institutional Repository: 116289, DOI: 10.1002/cnr2.1402, PubMed: 33939324)
24.	Shimon Takahashi, Kenshi Takechi, Natsumi Jozukuri, Takahiro Niimura, Masayuki Chuma, Mitsuhiro Goda, Yoshito Zamami, Yuki Izawa-Ishizawa, Masaki Imanishi, Yuya Horinouchi, Yasumasa Ikeda, Koichiro Tsuchiya, Hiroaki Yanagawa and Keisuke Ishizawa : Examination of the antiepileptic effects of valacyclovir using kindling mice- search for novel antiepileptic agents by drug repositioning using a large medical information database., European Journal of Pharmacology, Vol.902, 2021. (Summary) Despite the availability of more than 20 clinical antiepileptic drugs, approximately 30% of patients with epilepsy do not respond to antiepileptic drug treatment. Therefore, it is important to develop antiepileptic products that function via novel mechanisms. In the present study, we evaluated data from one of the largest global databases to identify drugs with antiepileptic effects, and subsequently attempted to understand the effect of the combination of antiepileptic drugs and valacyclovir in epileptic seizures using a kindling model. To induce kindling in mice, pentylenetetrazol at a dose of 40 mg/kg was administered once every 48 h. Valacyclovir was orally administered 30 min before antiepileptic drug injection in kindled mice, and behavioral seizures were monitored for 20 min following pentylenetetrazol administration. Additionally, c-Fos expression in the hippocampal dentate gyrus was measured in kindled mice. Valacyclovir showed inhibitory effects on pentylenetetrazol-induced kindled seizures. In addition, simultaneous use of levetiracetam and valacyclovir caused more potent inhibition of seizure activity, and neither valproic acid nor diazepam augmented the anti-seizure effect in kindled mice. Furthermore, kindled mice showed increased c-Fos levels in the dentate gyrus. The increase in c-Fos expression was significantly inhibited by the simultaneous use of levetiracetam and valacyclovir. The findings of the present study indicate that a combination of levetiracetam and valacyclovir had possible anticonvulsive effects on pentylenetetrazol-induced kindled epileptic seizures. These results suggest that valacyclovir may have an antiseizure effect in patients with epilepsy. (Tokushima University Institutional Repository) ● Metadata: 116301 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2021.174099 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33910036 ● Search Scopus @ Elsevier (PMID): 33910036 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejphar.2021.174099 (Tokushima University Institutional Repository: 116301, DOI: 10.1016/j.ejphar.2021.174099, PubMed: 33910036)
25.	Tomoko Funahashi, Toshihiro Koyama, Hideharu Hagiya, Ko Harada, Syunya Iinuma, Soichiro Ushio, Yoshito Zamami, Takahiro Niimura, Kazuaki Shinomiya, Keisuke Ishizawa, Toshiaki Sendo, Shiro Hinotsu and R Mitsunobu Kano : Population-Based Observational Study of Adverse Drug Event-Related Mortality in the Super-Aged Society of Japan., Drug Safety, Vol.44, No.5, 531-539, 2021. (Summary) The number of and trend in ADE-related deaths increased in Japan from 1999 to 2016, particularly in the older population. (Link to Publication Site) ● Publication site (DOI): 10.1007/s40264-020-01037-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33826081 ● Search Scopus @ Elsevier (PMID): 33826081 ● Search Scopus @ Elsevier (DOI): 10.1007/s40264-020-01037-9 (DOI: 10.1007/s40264-020-01037-9, PubMed: 33826081)
26.	Hirofumi Hamano, Yasumasa Ikeda, Mitsuhiro Goda, Keijo Fukushima, Seiji Kishi, Masayuki Chuma, Michiko Yamashita, Takahiro Niimura, Kenshi Takechi, Masaki Imanishi, Yoshito Zamami, Yuya Horinouchi, Izawa-Ishizawa Yuki, Licht Miyamoto, Ishizawa Keisuke, Hiromichi Fujino, Toshiaki Tamaki, Ken-ichi Aihara and Koichiro Tsuchiya : Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity, Kidney International, Vol.99, No.4, 885-889, 2021. (Summary) Cisplatin is widely used as an anti-tumor drug for the treatment of solid tumors. Unfortunately, it causes kidney toxicity as a critical side effect, limiting its use, given that no preventive drug against cisplatin-induced kidney toxicity is currently available. Here, based on a repositioning analysis of the Food and Drug Administration Adverse Events Reporting System, we found that a previously developed drug, diphenhydramine, may provide a novel treatment for cisplatin-induced kidney toxicity. To confirm this, the actual efficacy of diphenhydramine was evaluated in in vitro and in vivo experiments. Diphenhydramine inhibited cisplatin-induced cell death in kidney proximal tubular cells. Mice administered cisplatin developed kidney injury with significant dysfunction (mean plasma creatinine: 0.43 vs 0.15 mg/dl) and showed augmented oxidative stress, increased apoptosis, elevated inflammatory cytokines, and MAPKs activation. However, most of these symptoms were suppressed by treatment with diphenhydramine. Furthermore, the concentration of cisplatin in the kidney was significantly attenuated in diphenhydramine-treated mice (mean platinum content: 70.0 vs 53.4 μg/g dry kidney weight). Importantly, diphenhydramine did not influence or interfere with the anti-tumor effect of cisplatin in any of the in vitro or in vivo experiments. In a selected cohort of 98 1:1 matched patients from a retrospective database of 1467 patients showed that patients with malignant cancer who had used diphenhydramine before cisplatin treatment exhibited significantly less acute kidney injury compared to ones who did not (6.1 % vs 22.4 %, respectively). Thus, diphenhydramine demonstrated efficacy as a novel preventive medicine against cisplatin-induced kidney toxicity. (Tokushima University Institutional Repository) ● Metadata: 115399 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.kint.2020.10.041 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33307103 ● Search Scopus @ Elsevier (PMID): 33307103 ● Search Scopus @ Elsevier (DOI): 10.1016/j.kint.2020.10.041 (Tokushima University Institutional Repository: 115399, DOI: 10.1016/j.kint.2020.10.041, PubMed: 33307103)
27.	Mizuho Asada, Takahisa Mikami, Takahiro Niimura, Yoshito Zamami, Yoshihiro Uesawa, Masayuki Chuma and Keisuke Ishizawa : The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis., Oncology, 2021. (Summary) Our data suggest that the risk of ICI-related pneumonitis may increase in certain populations, including younger age (age <60 years) and ICIs users. These patients require careful monitoring. (Link to Publication Site) ● Publication site (DOI): 10.1159/000512633 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33477139 ● Search Scopus @ Elsevier (PMID): 33477139 ● Search Scopus @ Elsevier (DOI): 10.1159/000512633 (DOI: 10.1159/000512633, PubMed: 33477139)
28.	Takahisa Mikami, Bobby Liaw, Mizuho Asada, Takahiro Niimura, Yoshito Zamami, Deborah Green-LaRoche, Lori Pai, Michael Levy and Suriya Jeyapalan : Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database., Journal of Neuro-Oncology, Vol.152, No.1, 135-144, 2021. (Summary) ICI use is associated with a higher risk of neurological complications, with dual ICI therapy posing a higher risk, while older age, sex, or metastasis were not. Patients at older age, with certain cancer types, or on dual ICI therapy may be at higher risk of fatal neurologic AEs. (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-020-03687-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33423151 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099278956 (DOI: 10.1007/s11060-020-03687-2, PubMed: 33423151, Elsevier: Scopus)
29.	Masayuki Chuma, Kenshi Takechi, Kenta Yagi, Satoshi Sakaguchi, Hiroshi Nokihara, Chikako Kane, Yasutaka Sato, Takahiro Niimura, Mitsuhiro Goda, Yoshito Zamami, Keisuke Ishizawa and Hiroaki Yanagawa : Academic investigators' interest in promoting specified clinical trials : Questionnaire survey before and after implementation of the Clinical Trial Act, The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 71-75, 2021. (Summary) Background : Enforcement of the 2018 Clinical Trials Act (CTA) in Japan resulted in strict and complicated regulations surrounding intervention studies. Few Japan-specific measures have been developed to promote intervention studies in Japan despite concerns about CTA's negative influence on such studies. Therefore, this study examined the changes in academic investigators' interest in conducting clinical studies before and after enforcement of the CTA to determine measures to promote specified clinical trials. Methods : We conducted a questionnaire survey with investigators belonging to the Institute of Biomedical Sciences, Tokushima University Graduate School, before and after enforcement of the CTA. Results : Investigators had lesser interest in intervention studies in the post-questionnaire survey (post) group than in the pre-questionnaire survey (pre) group. Their desire for "project management" was significantly higher in the post-group than in the pre-group. Their desire for "support for preparing documents when conducting specified clinical trials" was significantly higher in the group interested in conducting specified clinical trials than that in the not-interested group. Conclusion : We revealed that investigators were highly interested in "project management" and "support for preparing documents when conducting specified clinical trials" after enforcement of the CTA. Measures for these desires may promote specified clinical trials. J. Med. Invest. 68 : 71-75, February, 2021. (Tokushima University Institutional Repository) ● Metadata: 115987 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.71 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994483 ● Search Scopus @ Elsevier (PMID): 33994483 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.71 (Tokushima University Institutional Repository: 115987, DOI: 10.2152/jmi.68.71, PubMed: 33994483)
30.	Hirofumi Hamano, Chisato Mitsuhashi, Yoshiko Suzuki, Yoshito Zamami, Kaito Tsujinaka, Naoto Okada, Takahiro Niimura, Tatsuya Hayama, Toru Imai, Shunsuke Ishida, Kumiko Sakamoto, Mitsuhiro Goda, Kenshi Takechi, Kenta Yagi, Masayuki Chuma, Yuya Horinouchi, Kazuaki Shinomiya, Yasumasa Ikeda, Yasushi Kirino, Toshimi Nakamura, Hiroaki Yanagawa, Yasuhiro Hamada and Keisuke Ishizawa : Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study., Biological & Pharmaceutical Bulletin, Vol.44, No.4, 478-484, 2021. (Summary) RAs in controlling multiple-day chemotherapy-induced nausea and vomiting. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b20-00609 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33790099 ● Search Scopus @ Elsevier (PMID): 33790099 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b20-00609 (DOI: 10.1248/bpb.b20-00609, PubMed: 33790099)
31.	Takayoshi Masuoka, Yuka Yamashita, Katsuya Nakano, Kenshi Takechi, Takahiro Niimura, Masashi Tawa, Qiang He, Keisuke Ishizawa and Takaharu Ishibashi : Chronic Tear Deficiency Sensitizes Transient Receptor Potential Vanilloid 1-Mediated Responses in Corneal Sensory Nerves., Frontiers in Cellular Neuroscience, Vol.14, 598678, 2020. (Summary) Chronic tear deficiency enhances the excitability of corneal cold-sensitive nerves that detect ocular dryness, which can lead to discomfort in patients with dry eye disease (DED). However, changes in corneal nerve excitations through the polymodal nociceptor "transient receptor potential vanilloid 1" (TRPV1) and the potential link between this receptor and symptoms of DED remain unclear. In this study, we examined the firing properties of corneal cold-sensitive nerves expressing TRPV1 and possible contributions of chronic tear deficiency to corneal nerve excitability by TRPV1 activation. The bilateral excision of lacrimal glands in guinea pigs decreased the tear volume and increased the frequency of spontaneous eyeblinks 1-4 weeks after surgery. An analysis of the firing properties of the cold-sensitive nerves was performed by single-unit recordings of corneal preparations 4 weeks after surgery in both the sham-operated and gland-excised groups. Perfusion of the TRPV1 agonist, capsaicin (1 μM), transiently increased the firing frequency in approximately 46-48% of the cold-sensitive nerves characterized by low-background activity and high threshold (LB-HT) cold thermoreceptors in both groups. Gland excision significantly decreased the latency of capsaicin-induced firing in cold-sensitive nerves; however, its magnitude was unchanged. Calcium imaging of cultured trigeminal ganglion neurons from both groups showed that intracellular calcium elevation of corneal neurons induced by a low concentration of capsaicin (0.03 μM) was significantly larger in the gland excision group, regardless of responsiveness to cold. An immunohistochemical study of the trigeminal ganglion revealed that gland excision significantly increased the proportion of corneal neurons enclosed by glial fibrillary acidic protein (GFAP)-immunopositive satellite glial cells. Topical application of the TRPV1 antagonist, A784168 (30 μM), on the ocular surface attenuated eye-blink frequency after gland excision. Furthermore, gland excision enhanced blink behavior induced by a low concentration of capsaicin (0.1 μM). These results suggest that chronic tear deficiency sensitizes the TRPV1-mediated response in the corneal LB-HT cold thermoreceptors and cold-insensitive polymodal nociceptors, which may be linked to dry eye discomfort and hyperalgesia resulting from nociceptive stimuli in aqueous-deficient dry eyes. (Tokushima University Institutional Repository) ● Metadata: 117446 (Link to Publication Site) ● Publication site (DOI): 10.3389/fncel.2020.598678 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33424555 ● Search Scopus @ Elsevier (PMID): 33424555 ● Search Scopus @ Elsevier (DOI): 10.3389/fncel.2020.598678 (Tokushima University Institutional Repository: 117446, DOI: 10.3389/fncel.2020.598678, PubMed: 33424555)
32.	Satoru Mitsuboshi, Takahiro Niimura, Yoshito Zamami and Keisuke Ishizawa : Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: analysis of the Japanese Adverse Drug Event Report database., British Journal of Clinical Pharmacology, 2020. (Summary) Limited information is available on anticoagulant-related nephropathy (ARN). We therefore reviewed the Japanese Adverse Drug Event Report database to investigate kidney injury (KI) in patients administered warfarin or direct oral anticoagulants (DOACs) and sought to clarify the risk factors for ARN. KI risk in warfarin users was associated with male sex (odds ratio [OR], 1.70; 95% confidence interval [CI], 1.35-2.13; P < 0.01) and age 80 years (OR, 1.35; 95% CI, 1.07-1.72; P = 0.01). KI risk in DOAC users was associated with body weight 80 kg (OR, 1.60; 95% CI, 1.01-2.53; P = 0.04) and use of dabigatran (OR, 1.61; 95% CI, 1.09-2.37; P < 0.01). Our findings suggest that risk factors for ARN differ between warfarin and DOACs, and that these risk factors may be associated with bleeding risk. Therefore, the risk of ARN may be decreased by better managing bleeding risk in patients taking anticoagulants. (Link to Publication Site) ● Publication site (DOI): 10.1111/bcp.14688 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33270271 ● Search Scopus @ Elsevier (PMID): 33270271 ● Search Scopus @ Elsevier (DOI): 10.1111/bcp.14688 (DOI: 10.1111/bcp.14688, PubMed: 33270271)
33.	Kenta Yagi, Marin Mitstui, Yoshito Zamami, Takahiro Niimura, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Masayuki Chuma, Kimiko Fukunaga, Takahiro Shibata, Shunsuke Ishida, Takumi Sakurada, Naoto Okada, Hirofumi Hamano, Yuya Horinouchi, Yasumasa Ikeda, Hiroaki Yanagawa and Keisuke Ishizawa : Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect., Cancer Medicine, 2020. (Summary) PPIs prevent hypertension in bevacizumab-treated patients but may reduce bevacizumab's anti-tumoral effects by inducing VEGF expression. (Tokushima University Institutional Repository) ● Metadata: 116288 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.3587 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33231381 ● Search Scopus @ Elsevier (PMID): 33231381 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.3587 (Tokushima University Institutional Repository: 116288, DOI: 10.1002/cam4.3587, PubMed: 33231381)
34.	Hiromi Hagiwara, Hidekatsu Fukuta, Hiroya Hashimoto, Takahiro Niimura, Yoshito Zamami, Keisuke Ishizawa, Takeshi Kamiya and Nobuyuki Ohte : A comparison of the safety and effectiveness of prasugrel and clopidogrel in younger population undergoing percutaneous coronary intervention: A retrospective study using a Japanese claims database., Journal of Cardiology, Vol.77, No.3, 285-291, 2020. (Summary) The safety and effectiveness of prasugrel was comparable to that of clopidogrel in real-world Japanese patients scheduled to undergo PCI. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2020.10.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34074484 ● Search Scopus @ Elsevier (PMID): 34074484 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jjcc.2020.10.001 (DOI: 10.1016/j.jjcc.2020.10.001, PubMed: 34074484)
35.	Satoru Mitsuboshi, Takahiro Niimura and Yoshito Zamami : Concomitant Use of Acetaminophen and Aspirin Increases Risk of Kidney Injury: Analysis of the Japanese Adverse Drug Event Report Database., Journal of Clinical Pharmacology, 2020. (Link to Publication Site) ● Publication site (DOI): 10.1002/jcph.1756 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33043465 ● Search Scopus @ Elsevier (PMID): 33043465 ● Search Scopus @ Elsevier (DOI): 10.1002/jcph.1756 (DOI: 10.1002/jcph.1756, PubMed: 33043465)
36.	Hiromi Hagiwara, Hidekatsu Fukuta, Takahiro Niimura, Yoshito Zamami, Keisuke Ishizawa, Kazunori Kimura, Takeshi Kamiya and Nobuyuki Ohte : Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases., International Journal of Medical Sciences, Vol.17, No.6, 728-733, 2020. (Summary) : The hemorrhagic risk was found to be greater with prasugrel than clopidogrel in real-world patients, including Japanese patients. (Tokushima University Institutional Repository) ● Metadata: 115153 (Link to Publication Site) ● Publication site (DOI): 10.7150/ijms.43168 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32218694 ● Summary page in Scopus @ Elsevier: 2-s2.0-85081614223 (Tokushima University Institutional Repository: 115153, DOI: 10.7150/ijms.43168, PubMed: 32218694, Elsevier: Scopus)
37.	Hirofumi Hamano, Takahiro Niimura, Yuya Horinouchi, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Masaki Imanishi, Masayuki Chuma, Yuki Izawa-Ishizawa, Licht Miyamoto, Keijo Fukushima, Hiromichi Fujino, Koichiro Tsuchiya, Keisuke Ishizawa, Toshiaki Tamaki and Yasumasa Ikeda : Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway, Toxicology Letters, Vol.318, 86-91, 2020. (Summary) Proton pump inhibitors (PPIs) have been used worldwide to treat gastrointestinal disorders. A recent study showed that long-term use of PPIs caused iron deficiency; however, it is unclear whether PPIs affect iron metabolism directly. We investigated the effect of PPIs on the peptide hepcidin, an important iron regulatory hormone. First, we used the FDA Adverse Event Reporting System database and analyzed the influence of PPIs. We found that PPIs, as well as H2 blockers, increased the odds ratio of iron-deficient anemia. Next, HepG2 cells were used to examine the action of PPIs and H2 blockers on hepcidin. PPIs augmented hepcidin expression, while H2 blockers did not. In fact, the PPI omeprazole increased hepcidin secretion, and omeprazole-induced hepcidin upregulation was inhibited by gene silencing or the pharmacological inhibition of the aryl hydrocarbon receptor. In mouse experiments, omeprazole also increased hepatic hepcidin mRNA expression and blood hepcidin levels. In mice treated with omeprazole, protein levels of duodenal and splenic ferroportin decreased. Taken together, PPIs directly affect iron metabolism by suppressing iron absorption through the inhibition of duodenal ferroportin via hepcidin upregulation. These findings provide a new insight into the molecular mechanism of PPI-induced iron deficiency. (Tokushima University Institutional Repository) ● Metadata: 113812 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.toxlet.2019.10.016 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31669099 ● Search Scopus @ Elsevier (PMID): 31669099 ● Search Scopus @ Elsevier (DOI): 10.1016/j.toxlet.2019.10.016 (Tokushima University Institutional Repository: 113812, DOI: 10.1016/j.toxlet.2019.10.016, PubMed: 31669099)
38.	Yoshito Zamami, Takahiro Niimura, Toshihiro Koyama, Yuta Shigemi, Yuki Izawa-Ishizawa, Mizuki Morita, Ayako Ohshima, Keisaku Harada, Toru Imai, Hiromi Hagiwara, Naoto Okada, Mitsuhiro Goda, Kenshi Takechi, Masayuki Chuma, Yutaka Kondo, Koichiro Tsuchiya, Shiro Hinotsu, R Mitsunobu Kano and Keisuke Ishizawa : Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database., Frontiers in Pharmacology, Vol.10, 2019. (Summary) The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of cardiac arrest patients, were extracted using "TargetMine," a drug discovery tool. We investigated whether the candidate drugs were among the drugs administered within 1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan Medical Data Center. Logistic regression analysis was performed, with the explanatory variables being the presence or absence of the administration of those candidate drugs that were administered to 10 patients and the objective variable being the "survival discharge." Adjusted odds ratios for survival discharge were calculated using propensity scores for drugs that significantly improved the proportion of survival discharge; the influence of covariates, such as patient background, medical history, and treatment factors, was excluded by the inverse probability-of-treatment weighted method. Using the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. Drugs not approved in Japan, oral medicines, and external medicines were excluded. Then, we investigated whether the candidate drugs were administered to the 2,227 cardiac arrest patients included in this study. The results of the logistic regression analysis showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that were administered to 10 patients showed significant association with improvement in the proportion of survival discharge. Further analyses using propensity scores revealed that the adjusted odds ratios for survival discharge for patients administered isosorbide dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel therapeutic agents for improving the prognosis of cardiac arrest patients. (Tokushima University Institutional Repository) ● Metadata: 114461 (Link to Publication Site) ● Publication site (DOI): 10.3389/fphar.2019.01257 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31780928 ● Summary page in Scopus @ Elsevier: 2-s2.0-85075592155 (Tokushima University Institutional Repository: 114461, DOI: 10.3389/fphar.2019.01257, PubMed: 31780928, Elsevier: Scopus)
39.	Yoshito Zamami, Takahiro Niimura, Naoto Okada, Toshihiro Koyama, Keijo Fukushima, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis., JAMA Oncology, 2019. (Link to Publication Site) ● Publication site (DOI): 10.1001/jamaoncol.2019.3113 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31436802 ● Search Scopus @ Elsevier (PMID): 31436802 ● Search Scopus @ Elsevier (DOI): 10.1001/jamaoncol.2019.3113 (DOI: 10.1001/jamaoncol.2019.3113, PubMed: 31436802)
40.	Naoto Okada, Takahiro Niimura, Yoshito Zamami, Hirofumi Hamano, Shunsuke Ishida, Mitsuhiro Goda, Kenshi Takechi, Masayuki Chuma, Masaki Imanishi and Keisuke Ishizawa : Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database., Cancer Medicine, 2018. (Summary) Breakpoint cluster region-Abelson murine leukemia (BCR-ABL) inhibitors markedly improve the prognosis of chronic myeloid leukemia. However, high treatment adherence is necessary for successful treatment with BCR-ABL inhibitors. Therefore, an adequate understanding of the adverse event profiles of BCR-ABL inhibitors is essential. Although many adverse events are observed in trials, an accurate identification of adverse events based only on clinical trial results is difficult because of strict entry criteria or limited follow-up durations. In particular, BCR-ABL inhibitor-induced impaired glucose metabolism remains controversial. Pharmacovigilance evaluations using spontaneous reporting systems are useful for analyzing drug-related adverse events in clinical settings. Therefore, we conducted signal detection analyses for BCR-ABL inhibitor-induced impaired glucose metabolism by using the FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) database. Signals for an increased reporting rate of impaired glucose metabolism were detected only for nilotinib use, whereas these signals were not detected for other BCR-ABL inhibitors. Subgroup analyses showed a clearly increased nilotinib-associated reporting rate of impaired glucose metabolism in male and younger patients. Although FAERS- and JADER-based signal detection analyses cannot determine causality perfectly, our study suggests the effects on glucose metabolism are different between BCR-ABL inhibitors and provides useful information for the selection of appropriate BCR-ABL inhibitors. (Tokushima University Institutional Repository) ● Metadata: 115037 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.1920 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30561126 ● Search Scopus @ Elsevier (PMID): 30561126 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.1920 (Tokushima University Institutional Repository: 115037, DOI: 10.1002/cam4.1920, PubMed: 30561126)
41.	Takahiro Niimura, Yoshito Zamami, Toru Imai, Tsuyoshi Ito, Hidenori Sagara, Hichiya Hiroyuki, Satoru Esumi, Kenshi Takechi, Masaki Imanishi, Toshihiro Koyama, Manabu Amano, Naomi Kurata, Yoshihisa Kitamura, Hironori Nakura, Toshiaki Sendo and Keisuke Ishizawa : Administration of Kampo medicine through a tube at an advanced critical care center., The Journal of Medical Investigation : JMI, Vol.65, No.1.2, 32-36, 2018. (Summary) n emergency and critical care medical centers, tube administration is employed for patients who have difficulty swallowing oral drugs owing to decreased consciousness or mechanical ventilation. However, tube clogging due to drug injection is a concern. We compared the crushing method with the simple suspension method for the passage of amlodipine, an antihypertensive drug, in combination with rikkunshito, which has been used to treat upper gastrointestinal disorders such as functional dyspepsia and gastroesophageal reflux in emergency and critical care medical centers, to ascertain the effect of Kampo products on the passage of other drugs during tube administration. When the crushing method was employed, poorly water-soluble solid products were formed, while a uniformly dispersed suspension was obtained using the simple suspension method. In addition, the passage rate of amlodipine through the tube was 64% and 93% in the crushing and simple suspension methods, respectively, thereby indicating that the simple suspension method provided more favorable than the crushing method. The results of this study suggested that the passage rate of amlodipine for patients who received Kampo products concurrently was higher when the simple suspension method was used, and an appropriate drug amount might well be able to administered to patients using this method. J. Med. Invest. 65:32-36, February, 2018. (Tokushima University Institutional Repository) ● Metadata: 111388 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.65.32 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29593190 ● Search Scopus @ Elsevier (PMID): 29593190 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.65.32 (Tokushima University Institutional Repository: 111388, DOI: 10.2152/jmi.65.32, PubMed: 29593190)
42.	Takahiro Niimura, Yoshito Zamami, Toru Imai, Kanako Nagao, Masafumi Kayano, Hidenori Sagara, Mitsuhiro Goda, Naoto Okada, Masayuki Chuma, Kenshi Takechi, Masaki Imanishi, Toshihiro Koyama, Tadashi Koga, Hironori Nakura, Toshiaki Sendo and Keisuke Ishizawa : Evaluation of the Benefits of De-Escalation for Patients with Sepsis in the Emergency Intensive Care Unit., Journal of Pharmacy & Pharmaceutical Sciences, Vol.21, No.1, 54-59, 2018. (Summary) The length of hospital stay after diagnosis was significantly shorter for the de-escalation group than for the non-de-escalation group. In the subgroup analysis, de-escalation for blood culture-positive patients was beneficial in terms of the length of hospital stay and length of antibiotic administration. (Link to Publication Site) ● Publication site (DOI): 10.18433/jpps29737 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29455711 ● Summary page in Scopus @ Elsevier: 2-s2.0-85044119660 (DOI: 10.18433/jpps29737, PubMed: 29455711, Elsevier: Scopus)
43.	Takahiro Niimura, Yoshito Zamami, Toshihiro Koyama, Yuki Izawa-Ishizawa, Masashi Miyake, Tadashi Koga, Keisaku Harada, Ayako Ohshima, Toru Imai, Yutaka Kondo, Masaki Imanishi, Kenshi Takechi, Keijo Fukushima, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Toshiaki Tamaki, Shiro Hinotsu, R Mitsunobu Kano and Keisuke Ishizawa : Hydrocortisone administration was associated with improved survival in Japanese patients with cardiac arrest., Scientific Reports, Vol.7, No.1, 2017. (Summary) There are few reports on hydrocortisone administration after cardiac arrest, and those that have been published included few subjects. This study aimed to evaluate the effect of hydrocortisone administration on the outcomes of patients who experienced cardiac arrest. We investigated the survival discharge rates and the length of hospital stay from cardiac arrest to discharge, stratified by use of hydrocortisone, using a Japanese health-insurance claims dataset that covers approximately 2% of the Japanese population. The study included the data of 2233 subjects who experienced either in-hospital or out-of-hospital cardiac arrest between January 2005 and May 2014. These patients were divided into two groups, based on the administration of hydrocortisone. We adjusted the baseline characteristics, medical treatment, and drug administration data of the two groups using propensity scores obtained via the inverse probability of treatment weighted method. The hydrocortisone group had a significantly higher survival discharge rate (13/61 [21.1%] vs. 240/2172 [11.0%], adjusted odds ratio: 4.2, 95% CI: 1.60-10.98, p = 0.004). In addition, the administration of hydrocortisone was independent predictor of survival to discharge (hazard ratio: 4.6, p < 0.001). The results demonstrate a correlation between hydrocortisone administration and the high rates of survival to discharge. (Tokushima University Institutional Repository) ● Metadata: 112397 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-017-17686-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29263333 ● Search Scopus @ Elsevier (PMID): 29263333 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-017-17686-3 (Tokushima University Institutional Repository: 112397, DOI: 10.1038/s41598-017-17686-3, PubMed: 29263333)
44.	Shiho Sato, Yoshito Zamami, Toru Imai, Satoshi Tanaka, Toshihiro Koyama, Takahiro Niimura, Masayuki Chuma, Tadashi Koga, Kenshi Takechi, Yasuko Kurata, Yutaka Kondo, Yuki Izawa-Ishizawa, Toshiaki Sendo, Hironori Nakura and Keisuke Ishizawa : Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia., Scientific Reports, Vol.7, No.1, 2017. (Summary) Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on their efficacies. Therefore, a meta-analysis was conducted. Relevant sources were identified from PubMed, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi. The outcomes were short-term and long-term survival in patients with shock-resistant ventricular fibrillation /pulseless ventricular tachycardia. Thirty-three studies were analysed. The results showed that, compared to the control treatment, AMD did not improve short-term survival (odds ratio (OR): 1.25, 95% confidence interval (CI): 0.91-1.71) or long-term survival (OR: 1.00, 95% CI: 0.63-1.57). However, compared to the control treatment, NIF significantly improved short-term survival (OR: 3.23, 95% CI: 2.21-4.72) and long-term survival (OR: 1.88, 95% CI: 1.36-2.59). No significant difference was observed in short-term survival (OR: 0.85, 95% CI: 0.63-1.15) or long-term survival (OR: 1.25, 95% CI: 0.67-2.31) between AMD- and NIF-treated patients. The results suggest that NIF is beneficial for short-term and long-term survival in shock-resistant ventricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in either outcome is not clear. (Tokushima University Institutional Repository) ● Metadata: 112393 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-017-13073-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28978927 ● Summary page in Scopus @ Elsevier: 2-s2.0-85030715238 (Tokushima University Institutional Repository: 112393, DOI: 10.1038/s41598-017-13073-0, PubMed: 28978927, Elsevier: Scopus)

Academic Letter:

1.	Hideharu Hagiya, Yuka Osaki, Michio Yamamoto, Takahiro Niimura, Ko Harada, Tsukasa Higashionna, Hirofumi Hamano, Yoshito Zamami, Shiro Hinotsu and Toshihiro Koyama : Global trends of seasonal influenza-associated mortality in 2001-2018: A longitudinal epidemiological study., The Journal of Infection, Vol.87, No.3, e54-e57, 2023. (Keyword) Humans / Influenza, Human / Seasons / Longitudinal Studies / Epidemiologic Studies (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jinf.2023.06.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37331427 ● Search Scopus @ Elsevier (PMID): 37331427 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jinf.2023.06.011 (DOI: 10.1016/j.jinf.2023.06.011, PubMed: 37331427)
2.	Satoru Mitsuboshi, Takahiro Niimura, Fuka Aizawa, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database., Basic & Clinical Pharmacology & Toxicology, Vol.130, No.4, 553-556, 2022. (Keyword) Adrenergic beta-Antagonists / Atenolol / Drug-Related Side Effects and Adverse Reactions / Female / Humans / Hypertension / Japan / Male / Renal Insufficiency, Chronic (Link to Publication Site) ● Publication site (DOI): 10.1111/bcpt.13717 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35174631 ● Search Scopus @ Elsevier (PMID): 35174631 ● Search Scopus @ Elsevier (DOI): 10.1111/bcpt.13717 (DOI: 10.1111/bcpt.13717, PubMed: 35174631)
3.	Satoru Mitsuboshi, Takahiro Niimura, Masaki Yoshino, Yoshika Sakamoto, Yoshito Zamami and Keisuke Ishizawa : Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database., International Journal of Clinical Pharmacy, Vol.44, No.1, 260-263, 2021. (Summary) Background The association between fluoropyrimidines except for capecitabine and the risk of hypertriglyceridemia is unclear. Objective To investigate hypertriglyceridemia in patients receiving fluoropyrimidines. Method This observational study used anonymized patient data recorded in the open-access Japanese Adverse Drug Event Report database. All fluoropyrimidine and taxane users were investigated. Results We identified 29,451 fluoropyrimidine users and 21,266 taxane users. Disproportionality for both hypertriglyceridemia and an increase in serum triglyceride levels was observed in fluoropyrimidine users compared with in taxane users (reporting odds ratio, 6.74; 95% confidence interval [CI] 2.05-22.17; P < .001). Multivariate logistic analysis showed that both hypertriglyceridemia and an increase in serum triglyceride levels among fluoropyrimidines users were significantly associated with doxifluridine use (odds ratio [OR] 42.50; 95% CI 5.34-338.00; P < .001), tegafur use (OR 9.56; 95% CI 2.08-43.90; P < .001), capecitabine use (OR 12.30; 95% CI 2.67-56.80; P < .001), and breast cancer (OR 5.61; 95% CI 1.07-29.50; P = .042). Conclusion This study suggests that the use of tegafur and doxifluridine is associated with an increased risk of hypertriglyceridemia similar to that with the use of capecitabine; in particular, fluoropyrimidine users with breast cancer may have a high risk of hypertriglyceridemia. (Keyword) Antineoplastic Combined Chemotherapy Protocols / Capecitabine / Fluorouracil / Humans / Hypertriglyceridemia / Japan / Tegafur (Link to Publication Site) ● Publication site (DOI): 10.1007/s11096-021-01324-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34482500 ● Search Scopus @ Elsevier (PMID): 34482500 ● Search Scopus @ Elsevier (DOI): 10.1007/s11096-021-01324-0 (DOI: 10.1007/s11096-021-01324-0, PubMed: 34482500)

Review, Commentary:

1.	Hirofumi Hamano, Yoshito Zamami, Soichiro Ushio, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : [Development of Preventive Methods for Drug-induced Cardiotoxicity Using a Large-scale Medical Information Database]., Journal of the Pharmaceutical Society of Japan, Vol.144, No.3, 257-264, 2024. (Summary) Cancer therapies have evolved considerably thereby substantially improving the survival of patients with cancer. However, cardiotoxicity, such as myocarditis and heart failure, induced by anticancer drugs, including immune checkpoint inhibitor(ICI)s and doxorubicin, present serious challenges. Numerous observations have indicated increased risks of cardiotoxicity- and cancer-related mortality in patients with drug-induced cardiotoxicity. Therefore, the prevention and management of drug-induced cardiotoxicity should be prioritized to enable sustainable long-term treatment while preserving patients' quality of life. Recently, medical research has been primarily focused on elucidation of therapeutic benefits and adverse events using medical big data, including worldwide databases of adverse events. The aim of the present study was to establish prevention strategies for drug-induced cardiotoxicity and advance data analytics. A data-driven approach was adopted to comprehensively analyze patient data and drug-induced cardiotoxicity. These data analytics revealed numerous risk factors, leading to the development of drugs that mitigate these factors. Furthermore, many unknown adverse events with molecularly targeted drugs were brought to light. Consequently, the importance of managing adverse events, guided by insights from data science, is predicted to increase. In this symposium review, we introduce our research exemplifying pharmaceutical studies utilizing medical big data. In particular, we discuss in detail the risk factors associated with myocarditis induced by immune checkpoint inhibitors along with prophylactic agents to mitigate doxorubicin-induced cardiotoxicity. (Keyword) Humans / Cardiotoxicity / Myocarditis / quality of life / Doxorubicin / Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1248/yakushi.23-00164-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38432934 ● Search Scopus @ Elsevier (PMID): 38432934 ● Search Scopus @ Elsevier (DOI): 10.1248/yakushi.23-00164-2 (DOI: 10.1248/yakushi.23-00164-2, PubMed: 38432934)
2.	Yoshito Zamami, Hirofumi Hamano, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Drug-Repositioning Approaches Based on Medical and Life Science Databases., Frontiers in Pharmacology, Vol.12, No.752174, Nov. 2021. (Tokushima University Institutional Repository) ● Metadata: 116895 (Link to Publication Site) ● Publication site (DOI): 10.3389/fphar.2021.752174 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3389/fphar.2021.752174 (Tokushima University Institutional Repository: 116895, DOI: 10.3389/fphar.2021.752174)
3.	Yoshito Zamami, Takahiro Niimura, Kenshi Takechi, Masaki Imanishi, T Koyama and Keisuke Ishizawa : Drug repositioning research to improve the survival rate after cardiopulmonary arrest - utilizing large scale Medical Claims Database -, Journal of the Pharmaceutical Society of Japan, Vol.137, No.12, 1439-1442, 2017. (Summary) Approximately 100000 people suffer cardiopulmonary arrest in Japan every year, and the aging of society means that this number is expected to increase. Worldwide, approximately 100 million develop cardiac arrest annually, making it an international issue. Although survival has improved thanks to advances in cardiopulmonary resuscitation, there is a high rate of postresuscitation encephalopathy after the return of spontaneous circulation, and the proportion of patients who can return to normal life is extremely low. Treatment for postresuscitation encephalopathy is long term, and if sequelae persist then nursing care is required, causing immeasurable economic burdens as a result of ballooning medical costs. As at present there is no drug treatment to improve postresuscitation encephalopathy as a complication of cardiopulmonary arrest, the development of novel drug treatments is desirable. In recent years, new efficacy for existing drugs used in the clinical setting has been discovered, and drug repositioning has been proposed as a strategy for developing those drugs as therapeutic agents for different diseases. This review describes a large-scale database study carried out following a discovery strategy for drug repositioning with the objective of improving survival rates after cardiopulmonary arrest and discusses future repositioning prospects. (Keyword) Databases, Factual / Drug Repositioning / Heart Arrest / Humans / Hypoxia-Ischemia, Brain / Japan / Research Design / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1248/yakushi.17-00139-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29199254 ● Summary page in Scopus @ Elsevier: 2-s2.0-85037339843 (DOI: 10.1248/yakushi.17-00139-3, PubMed: 29199254, Elsevier: Scopus)

Proceeding of International Conference:

1.	Takahiro Niimura, Koji Miyata, Kenta Yagi, Fuka Aizawa, Kei Kawada, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Evaluation of cardiovascular toxicity profile of ALK inhibitors using adverse event reporting database., ASCPT 2024 Annual Meeting Colorado Springs March 2024, Colorado Springs, Mar. 2024.
2.	Koji Miyata, Yuki Izawa-Ishizawa, Honoka Nishi, Shuto Itokazu, Tatsumi Miyata, Kaito Tsujinaka, Masateru Kondo, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : Fluoroquinolones attribute aortic diseases through endothelial dysfunction., ASCPT 2024 Annual Meeting, Colorado Springs, Mar. 2024.
3.	Kei Kawada, Ishida Tomoaki, Morisawa Shumpei, Jobu Kohei, Higasi Youichirou, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : Atractylodes lancea Rhizome-derived Exosome-like Nanoparticles Suppress Lipopolysaccharide-induced Inflammation in Murine Microglial Cells, 81st FIP World Congress of Pharmacy and Pharmaceutical Sciences., Brisbane, Sep. 2023.
4.	Masayuki Chuma, Mitsuhiro Goda, Yoshito Zamami, Kenshi Takechi, Hirofumi Hamano, Ishida Shunsuke, Takahiro Niimura, Kondo Masateru, Bando Takashi, Yuki Izawa-Ishizawa, Tasaki Yoshikazu and Keisuke Ishizawa : Identification of prophylactic drug for vancomycin- associated nephrotoxicity using big data analysis., 19th World Congress of Basic & Clinical Pharmacology (WCP2023), Glasgow, Jul. 2023.
5.	Mitsuhiro Goda, Kanda Masaya, Yoshioka Toshihiko, Miyata Koji, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Sakurada Takumi and Yuki Izawa-Ishizawa : Discovery of preventive drugs for cisplatin-induced acute kidney injury., 19th World Congress of Basic & Clinical Pharmacology (WCP2023), Glasgow, Jul. 2023.
6.	Miyata Koji, Yuki Izawa-Ishizawa, Takahiro Niimura, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : Investigation of PDE5 Inhibitors and Artery Diseases Using Real-World Database, 19th World Congress of Basic & Clinical Pharmacology (WCP2023), Glasgow, Jul. 2023.
7.	Imakura Takeshi, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Murakami Kojin, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis, ERS International Congress 2022, Barcelona, Sep. 2022.
8.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Computational Drug Repositioning Approach Identifies Polo-Like KinaseInhibitors as Potential Therapeutics for Pulmonary Fibrosis, ATS 2022 International Conference, San Francisco, May 2022.
9.	Imakura Takeshi, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kohjin Murakami, Yuya Yamashita, Takahashi Naoki, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice, APSR 2021, Kyoto and online, Nov. 2021.

Proceeding of Domestic Conference:

1.	Kenta Yagi, Sayaka Imawaka, Mayu Takaoka, Naoki Okamoto, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Kei Kawada, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Bcr-Abl 阻害剤に対する慢性骨髄性白血病細胞の耐性獲得メカニズムの探索, 第144回日本薬理学会近畿部会, Mar. 2024.
2.	Yuki Izawa-Ishizawa, Koji Miyata, Kaito Tsujinaka, Shuto Itokazu, Tatsumi Miyata, Masateru Kondoh, Takahiro Niimura, Toshihiko Yoshioka, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬による大動脈疾患リスクに関する2つの矛盾, 第144回日本薬理学会近畿部会, Mar. 2024.
3.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, Kenta Yagi, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa, Kei Kawada and Keisuke Ishizawa : HMG-CoA還元酵素阻害剤はGST を介して抗がん剤誘発性機械的刺激応答閾値低下を改善する, 第144回日本薬理学会近畿部会, Mar. 2024.
4.	Tatsumi Miyata, Yuki Izawa-Ishizawa, Koji Miyata, Shuto Itokazu, Kaito Tsujinaka, Himeno Fukuoka, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : レボフロキサシンの血管炎症への影響, 第268回徳島医学会, Mar. 2024.
5.	Shuto Itokazu, Yuki Izawa-Ishizawa, Koji Miyata, Tatsumi Miyata, Masateru Kondoh, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : 杜仲葉エキスによる大動脈疾患発症抑制効果の検討, 第268回徳島医学会, Mar. 2024.
6.	Koji Miyata, Yuki Izawa-Ishizawa, Honoka Nishi, Shuto Itokazu, Tatsumi Miyata, Kaito Tsujinaka, Masateru Kondoh, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬に関連した大動脈瘤解離には内皮障害が関与する, 第97回日本薬理学会年会第44回日本臨床薬理学会学術総会, Dec. 2023.
7.	Kei Kawada, 石田智滉, 福田仁, 兵頭勇己, 浜田知幸, 久保亨, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Mitsuhiro Goda and Keisuke Ishizawa : 機械学習解析を用いた心不全治療薬の年齢別有効性の検討―高知急性非代償性心不全レジストリ研究より―, 第97回日本薬理学会年会第44回日本臨床薬理学会学術総会, Dec. 2023.
8.	杉本祐悟, Mitsuhiro Goda, 石田朋奈, 加納菜々, Masaya Kanda, Toshihiko Yoshioka, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Yuki Izawa-Ishizawa and Keisuke Ishizawa : SGLT2阻害薬によるシスプラチン誘発腎障害の抑制効果, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
9.	Kenta Yagi, Takahiro Niimura, Satoshi Sakaguchi, Fuka Aizawa, Kei Kawada, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : リアルワールドデータの医療への活用に向けて, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
10.	Kei Kawada, 石田智滉, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来細胞外膜小胞を用いた抗神経炎症治療薬の開発, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
11.	Takahiro Niimura : 医療データを活用した臨床薬理学研究, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
12.	Kei Kawada, 石田智滉, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来細胞外膜小胞を用いた抗神経炎症治療薬の開発, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
13.	Toshihiko Yoshioka, Mitsuhiro Goda, Tomona Ishida, Yugo Sugimoto, 神田将哉, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの予防効果, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
14.	Yugo Sugimoto, Mitsuhiro Goda, Tomona Ishida, 加納菜々, 神田将哉, Toshihiko Yoshioka, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 慢性骨髄性白血病の薬剤耐性に有用な薬剤の探索, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
15.	友近七海, Fuka Aizawa, SONODA Yuhei, NISHIBASHI Ayaka, MIYAUCHI Kanaho, Mitsuhiro Goda, Kenta Yagi, Takahiro Niimura, Yuki Izawa-Ishizawa, 朝田瑞穂, 植沢芳広 and Keisuke Ishizawa : 実験的多発性硬化症モデルマウスに対するウルソデオキシコール酸の治療効果の検討, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
16.	Honoka Nishi, Fuka Aizawa, Yuki Izawa-Ishizawa, TSUJINAKA Kaito, MIYATA Koji, Toshihiko Yoshioka, Masateru Kondoh, Shuto Itokazu, MIYATA Tatsumi, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : 血管新生阻害剤による大動脈解離発症のリスク因子解明, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
17.	森山大嗣, Fuka Aizawa, Ami Okabayashi, Mitsuhiro Goda, Kenta Yagi, Takahiro Niimura, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 抗がん剤誘発性末梢神経障害に対するスタチン系薬剤の有効性ならびに作用標的の検討, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
18.	Kazushi Uchida, Hiroto Unten, Hirofumi Hamano, Takahiro Niimura, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 免疫チェックポイント阻害剤関連心筋炎モデルマウスの作製とモデルマウスを用いた予防薬探索, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
19.	Takahiro Niimura, MIYATA Koji, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : 有害事象報告データベースを活用したALK阻害薬の心血管毒性プロファイル解明, 生体機能と創薬シンポジウム2023, Aug. 2023.
20.	Toshihiko Yoshioka, Mitsuhiro Goda, Yugo Sugimoto, Tomona Ishida, 神田将哉, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの予防効果, 生体機能と創薬シンポジウム2023, Aug. 2023.
21.	BANDO Hiroshi, Mitsuhiro Goda, Takahiro Niimura, 新田侑生, Masayuki Chuma, 北川航平, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, 櫻田巧 and Keisuke Ishizawa : 大規模医療情報データベース解析を基盤としたラモトリギンの皮膚障害発現リスクに影響する薬剤の探索, 生体機能と創薬シンポジウム2023, Aug. 2023.
22.	Toshihiko Yoshioka, Mitsuhiro Goda, 神田将哉, Yugo Sugimoto, Yuki Izawa-Ishizawa, Kenta Yagi, Fuka Aizawa, MIYATA Koji, Takahiro Niimura, 櫻田巧, 桐野靖 and Keisuke Ishizawa : バルプロ酸ナトリウムのシスプラチン誘発腎障害予防薬としての可能性, 第267回徳島医学会学術集会, Aug. 2023.
23.	神田将哉, Mitsuhiro Goda, 吉岡俊彦, Yugo Sugimoto, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : MATE型輸送体を標的とするシスプラチン誘発腎障害予防戦略の開発, 第32回霧島神経薬理フォーラム, Aug. 2023.
24.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, Kenta Yagi, Mitsuhiro Goda, Takahiro Niimura, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 抗がん剤誘発性末梢神経障害に対するHMG-CoA還元酵素阻害剤の多面的作用, 第2回あべの薬理学懇話会, Aug. 2023.
25.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, Kenta Yagi, 高橋志門, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : スタチンはOxaliplatin および Paclitaxel 誘発性末梢神経障害を改善する, 医療薬学フォーラム2023 / 第31回クリニカルファーマシーシンポジウム, Jul. 2023.
26.	Kei Kawada, 石田智滉, 常風興平, 森沢惇平, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来Exosome-like Nanoparticles (ELNs)の医療への応用 -蒼朮由来ELNsによる抗神経炎症作用の検討-, 第143回日本薬理学会近畿部会, Jun. 2023.
27.	Kei Kawada, 石田智滉, 常風興平, 森沢惇平, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来Exosome-like Nanoparticles (ELNs)の医療への応用 -蒼朮由来ELNsによる抗神経炎症作用の検討-, 第143回日本薬理学会近畿部会, Jun. 2023.
28.	OKAMOTO Naoki, Kenta Yagi, Sayaka Imawaka, Mayu Takaoka, Yurika Kuniki, Yuki Izawa-Ishizawa, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda and Keisuke Ishizawa : 慢性骨髄性白血病に対する新規分子標的治療薬の耐性メカニズムの探索, 第143回日本薬理学会近畿部会, Jun. 2023.
29.	Yoshika Sakamoto, Nanami Tomochika, Takahiro Niimura, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : スニチニブ誘発心毒性に対する新規予防薬の探索と作用機序の検討, 日本医療薬学会第6回フレッシャーズ・カンファランス, Jun. 2023.
30.	Hiroto Unten, Kazushi Uchida, Hirofumi Hamano, Takahiro Niimura, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 免疫チェックポイント阻害剤関連心筋炎モデルマウスの確立と病理組織像の評価, 日本医療薬学会第6回フレッシャーズ・カンファランス, Jun. 2023.
31.	Yoshito Zamami, Hirofumi Hamano, 牛尾聡一郎, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 大規模医療情報データベースを用いた薬剤性心毒性の予防法の開発, 日本薬学会第143年会, Mar. 2023.
32.	Kenta Yagi, Mayu Takaoka, 吉武愛哉, 丸尾陽成, Rie Andou, Fuka Aizawa, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : プロトンポンプ阻害剤およびボノプラザンがVEGF発現に与える影響, 日本薬学会第143年会, Mar. 2023.
33.	Fuka Aizawa, 岡林亜美, Daishi Moriyama, Kenta Yagi, Mitsuhiro Goda, NITTA Ayaka, Takahiro Niimura, 石澤有紀 and 石澤啓介 : 抗がん剤誘発性末梢神経障害克服に向けたスタチン系薬剤による有効性検討, 日本薬学会第143年会, Mar. 2023.
34.	Mitsuhiro Goda, 糸林小友理, 神田将哉, 吉岡俊彦, 杉本祐悟, 石田朋奈, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa, Takumi Sakurada, 桐野靖 and Keisuke Ishizawa : バルプロ酸ナトリウムのシスプラチン誘発腎障害に対する予防効果の作用機序解明, 日本薬学会第143年会, Mar. 2023.
35.	Takahiro Niimura, Hiroto Unten, Hirofumi Hamano, Kazushi Uchida, Nanami Tomochika, MIYATA Koji, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 遺伝子改変マウスを用いた免疫チェックポイント阻害剤関連心筋炎の病態モデル開発, 日本薬学会第143年会, Mar. 2023.
36.	MIYATA Koji, Yuki Izawa-Ishizawa, Hirofumi Hamano, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : ホスホジエステラーゼ5阻害剤に関連した動脈疾患, 日本薬学会第143年会, Mar. 2023.
37.	Fuka Aizawa, Kenta Yagi, Takahiro Niimura, Mitsuhiro Goda, Yoshito Zamami, Yuki Izawa-Ishizawa and Keisuke Ishizawa : データサイエンス×基礎によるCIPN支持療法薬の創出, 日本薬学会第143年会, Jan. 2023.
38.	Takahiro Niimura, Hiroto Unten, Hirofumi Hamano, Kazushi Uchida, MIYATA Koji, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and 石澤啓介 : PD-1ノックアウトマウスを用いた免疫チェックポイント阻害剤関連心筋炎の新規病態モデル開発, 第32回日本循環薬理学会, Jan. 2023.
39.	八木健太, Fuka Aizawa, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : VEGF発現にプロトンポンプ阻害剤が与える影響, 第32回日本循環薬理学会, Jan. 2023.
40.	Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Fuka Aizawa, 櫻田巧, 小川敦, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : がん薬物療法に伴う腎障害とその予防, 第96回日本薬理学会年会/第43回日本臨床薬理学学術総会シンポジウム6, Nov. 2022.
41.	Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Takahiro Niimura, 櫻田巧, 小川敦, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータ解析と基礎研究を融合した研究手法によるハイブリッド創薬, 第96回日本薬理学会年会/第43回日本臨床薬理学学術総会日本臨床薬理学会共催シンポジウム(シンポジウム41), Nov. 2022.
42.	Naoto Okada, Shingen Nakamura, Taro Shimizu, Hidenori ANDO, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Tatsuhiro Ishida and Keisuke Ishizawa : 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に関連する因子の検討, 第32回日本医療薬学学会, Sep. 2022.
43.	Naoto Okada, Shingen Nakamura, Taro Shimizu, Hidenori ANDO, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Tatsuhiro Ishida and Keisuke Ishizawa : 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に影響を与える因子の検討, 第32回日本医療薬学会年会, Sep. 2022.
44.	椋田千晶, 小川敦, Mitsuhiro Goda, Toshihiko Yoshioka, Takahiro Niimura, 牛尾聡一郎, 江角悟, Naoto Okada, Yoshito Zamami and Keisuke Ishizawa : 有害事象自発報告データベースを用いたダントロレン誘発高カリウム血症に影響を与える因子の解析, 第32回日本医療薬学会年会, Sep. 2022.
45.	Kenta Yagi, 丸尾陽成, 石田俊介, 鍛治園誠, Fuka Aizawa, MIYATA Koji, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : ベバシズマブ治療継続にプロトンポンプ阻害剤，ボノプラザンが与える影響, 第32回日本医療薬学会年会, Sep. 2022.
46.	山川裕介, Kenta Yagi, Toshihiko Yoshioka, 佐藤真希, 丸尾陽成, MIYATA Koji, Fuka Aizawa, Yurika Kuniki, Takahiro Niimura, Satoshi Sakaguchi, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : 慢性骨髄性白血病患者における Bcr-Abl 阻害剤治療期間とアルコール摂取の関連, 第32回日本医療薬学会年会, Sep. 2022.
47.	Takahiro Niimura : 医療ビッグデータを活用した心肺停止患者の新規治療法の開発, 第32回日本医療薬学会年会 Postdoctoral Award受賞講演, Sep. 2022.
48.	Mitsuhiro Goda, Masaya Kanda, 吉岡俊彦, Takahiro Niimura, 櫻田巧, 小川敦, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 薬物療法の最適化を目指すリアルワールドデータ駆動型臨床薬理学研究, 第32回日本医療薬学会年会シンポジウム32, Sep. 2022.
49.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, SONODA Yuhei, Shimon Takahashi, Takahiro Niimura, Mitsuhiro Goda, Yoshito Zamami, Toshihiko Yoshioka, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 臨床薬理の視点で実践する創薬研究:抗がん剤有害事象をターゲットとしたトランスレーショナルリサーチ, 第32回日本医療薬学会年会シンポジウム55, Sep. 2022.
50.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, SONODA Yuhei, Shimon Takahashi, NITTA Ayaka, Mitsuhiro Goda, Kenta Yagi, Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa and Keisuke Ishizawa : スタチンの pleiotropic effects: 抗がん剤誘発性末梢神経障害抑制作用の検討, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
51.	神田将哉, Mitsuhiro Goda, Toshihiko Yoshioka, 小川敦, 石田俊介, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータ解析を基盤としたシスプラチン誘発腎障害予防薬の探索, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
52.	Takashi Bandoh, Masayuki Chuma, Mitsuhiro Goda, Tomomi Tani, Yurika Kuniki, 小川敦, 櫻田巧, Fuka Aizawa, Takahiro Niimura, 八木健太, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータ解析および基礎研究を融合したバンコマイシン関連腎障害に対する予防薬探索, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
53.	MIYATA Koji, Yuki Izawa-Ishizawa, TSUJINAKA Kaito, Kohei Ohmine, Honoka Nishi, Shuto Itokazu, Takahiro Niimura, Masateru Kondoh, Fuka Aizawa, Hirofumi Hamano, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬に関連した動脈瘤・解離の病態解明, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
54.	Sayuri Itobayashi, Mitsuhiro Goda, Yugo Sugimoto, 石田朋奈, 神田将哉, Toshihiko Yoshioka, 小川敦, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : シスプラチン誘発急性腎障害に対するバルプロ酸ナトリウムの予防効果, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
55.	Yurika Kuniki, Kenta Yagi, Mayu Takaoka, OKAMOTO Naoki, Hirofumi Hamano, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 慢性骨髄性白血病に対する既存承認薬とALDH阻害剤併用の有効性, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
56.	Toshihiko Yoshioka, Mitsuhiro Goda, Sayuri Itobayashi, Yugo Sugimoto, Tomona Ishida, 神田将哉, 小川敦, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 薬剤性腎障害予防を志向したドラッグリポジショニング研究, 第31回霧島神経薬理フォーラム, Aug. 2022.
57.	MIYATA Koji, Yuki Izawa-Ishizawa, TSUJINAKA Kaito, Kohei Ohmine, Honoka Nishi, Shuto Itokazu, Takahiro Niimura, 近藤正輝, Fuka Aizawa, Hirofumi Hamano, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : 関連した動脈瘤・動脈解離:医療ビッグデータ解析と基礎薬理学実験によるアプローチ, 第29回市大フォーラム, Aug. 2022.
58.	Mitsuhiro Goda, 神田将哉, Toshihiko Yoshioka, Ami Yoshida, Sayuri Itobayashi, Takahiro Niimura, 櫻田巧, 小川敦, Naoto Okada, Fuka Aizawa, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 遺伝子発現および大規模医療情報データベースを活用したシスプラチン関連腎障害に対する予防薬の探索, 第51回日本心脈管作動物質学会学術集会, Jul. 2022.
59.	Kenta Yagi, Mayu Takaoka, 丸尾陽成, Fuka Aizawa, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : プロトンポンプ阻害剤，ボノプラザンが抗VEGF療法に与える影響, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, Jul. 2022.
60.	Yoshika Sakamoto, Nanami Tomochika, Takahiro Niimura, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Shiori Nishiuchi, 生田賢治, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータを活用したスニチニブ誘発心毒性に対する予防薬の探索, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, Jul. 2022.
61.	Yurika Kuniki, Kenta Yagi, Mayu Takaoka, OKAMOTO Naoki, Hirofumi Hamano, Mitsuhiro Goda, Takahiro Niimura, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 慢性骨髄性白血病に対するBCR-ABL阻害剤とALDH阻害剤併用による抗腫瘍効果増強の検討, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, Jul. 2022.
62.	Hiroto Unten, Hirofumi Hamano, Takahiro Niimura, Nanami Tomochika, Shiori Nishiuchi, Mitsuhiro Goda, Kenta Yagi, 相澤風花, Yoshito Zamami and Keisuke Ishizawa : 大規模医療情報データベースを用いたドキソルビシン誘発性心筋症に対する予防薬の開発, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウムシンポジウム 2, Jul. 2022.
63.	MIYATA Koji, Yuki Izawa-Ishizawa, 近藤正輝, TSUJINAKA Kaito, Kohei Ohmine, 西穂香, Shuto Itokazu, Takahiro Niimura, Fuka Aizawa, Hirofumi Hamano, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬による血管毒性の病態解明, 第141回日本薬理学会近畿部会, Jul. 2022.
64.	Hiroto Unten, Hirofumi Hamano, Takahiro Niimura, Kazushi Uchida, Nanami Tomochika, MIYATA Koji, 石田俊介, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yoshito Zamami and Keisuke Ishizawa : 免疫チェックポイント阻害剤関連心筋炎の解析に適した実験的病態モデルの開発, 第141回日本薬理学会近畿部会, Jul. 2022.
65.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : In silico解析により同定されたPLK阻害剤のブレオマイシン誘発肺線維症モデルマウスにおける効果の検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
66.	Yoshika Sakamoto, Nanami Tomochika, Hirofumi Hamano, Mitsuhiro Goda, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Akihito Nakamura, Shiori Nishiuchi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 大規模医療情報データベースを用いたスニチニブ誘発心不全に対する予防薬の探索, 第95回日本薬理学会年会, Mar. 2022.
67.	Yurika Kuniki, Kenta Yagi, Rina Yoshida, OKAMOTO Naoki, Rie Andou, 山川裕介, Hirofumi Hamano, Mitsuhiro Goda, Takahiro Niimura, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 慢性骨髄性白血病に対するBCR-ABL阻害剤とALDH阻害剤併用による抗腫瘍効果, 第95回日本薬理学会年会, Mar. 2022.
68.	Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Takahiro Niimura, 櫻田巧, 小川敦, Naoto Okada, Fuka Aizawa, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータ解析と基礎研究を融合した研究手法による抗がん剤誘発副作用に対する予防法の探索, 日本臨床腫瘍薬学会学術大会2022 シンポジウム 12, Mar. 2022. (Keyword) data analysis
69.	Shiori Nishiuchi, Hiroumi Saito, Takahiro Niimura, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yuki Izawa-Ishizawa and Keisuke Ishizawa : ドキソルビシン誘発心筋症に対する予防薬探索を目的としたドラッグリポジショニング研究, 第42回日本臨床薬理学会学術総会, Dec. 2021.
70.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kohjin Murakami, Naoki Takahashi, Kozo Kagawa, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : In silico 解析を用いた肺線維症に対する新規治療薬の探索, 第1回日本びまん性肺疾患研究会, Oct. 2021.
71.	Tomomi Tani, Masayuki Chuma, Mitsuhiro Goda, Takashi Bandoh, Masateru Kondoh, Yurika Kuniki, Hirofumi Hamano, Takahiro Niimura, Naoto Okada, Fuka Aizawa, Kenta Yagi and Keisuke Ishizawa : ビッグデータ解析を活用したバンコマイシン関連腎障害に対する予防薬の探索とその有用性の検討, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) data analysis
72.	Haruna Kajimoto, Daishi Moriyama, Fuka Aizawa, Takahiro Niimura, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa and Keisuke Ishizawa : FAERS解析を活用したオキサリプラチン誘発末梢神経障害に対する予防薬の検討, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) data analysis
73.	Hiroto Unten, Hirofumi Hamano, Takahiro Niimura, Nanami Tomochika, Shiori Nishiuchi, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yoshito Zamami and Keisuke Ishizawa : Exploration of prophylactic drugs against doxorubicin-induced cardiomyopathy using largescale medical databases, 第15回次世代を担う若手のための医療薬科学シンポジウム, Oct. 2021.
74.	Fuka Aizawa, Haruna Kajimoto, Daishi Moriyama, Takahiro Niimura, Mitsuhiro Goda, NITTA Ayaka, Shimon Takahashi, Hirofumi Hamano, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータを基盤とした迅速かつ安全ながん支持療法の開発, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis
75.	Yoshito Zamami, Takahiro Niimura, Hirofumi Hamano, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : リアルワールドデータを活用したドラッグリポジショニング研究, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis
76.	Masayuki Chuma, Aki Nakamoto, Takashi Bandoh, Takahiro Niimura, Naoto Okada, Fuka Aizawa, Hirofumi Hamano, Kenta Yagi, Mitsuhiro Goda, Yoshito Zamami, Keisuke Ishizawa and Yoshikazu Tasaki : メタアナリシスとデータベース解析の融合によるハイインパクトエビデンスの創出, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis
77.	Masaya Kanda, Mitsuhiro Goda, Toshihiko Yoshioka, Ami Yoshida, Takahiro Niimura, Takumi Sakurada, Atsushi Ogawa, Naoto Okada, Fuka Aizawa, Yoshito Zamami, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 抗がん剤副作用予防のための大規模医療情報データベース解析を活用したリバーストランスレーショナルリサーチ, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis / kidney disease
78.	Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Ami Yoshida, Takahiro Niimura, Takumi Sakurada, Atsushi Ogawa, Naoto Okada, Fuka Aizawa, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 大規模医療情報データベースを活用した抗がん剤副作用に対する予防法の確立, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) data analysis / kidney disease
79.	TSUJINAKA Kaito, Yuki Izawa-Ishizawa, Takahiro Niimura, Toshihiko Yoshioka, Mitsuhiro Goda, Masateru Kondoh, Kohei Ohmine, Honoka Nishi, MIYATA Koji, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yoshito Zamami and Keisuke Ishizawa : 血管新生阻害剤における大動脈解離発症の関連要因解明, 第50回日本心脈管作動物質学会, Jul. 2021.
80.	Haruna Kajimoto, Daishi Moriyama, Fuka Aizawa, Takahiro Niimura, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa and Keisuke Ishizawa : オキサリプラチン誘発末梢神経障害に対するスタチン系薬剤の予防効果, 第139回日本薬理学会近畿部, Jun. 2021. (Keyword) data analysis / kidney disease
81.	Tomomi Tani, Masayuki Chuma, Mitsuhiro Goda, Takashi Bandoh, Masateru Kondoh, Yurika Kuniki, Hirofumi Hamano, Takahiro Niimura, Naoto Okada, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 大規模医療情報および遺伝子発現データベースを活用したバンコマイシン関連腎障害に対する予防薬の探索とソの有用性の検討, 第139回日本薬理学会近畿部, Jun. 2021. (Keyword) data analysis / kidney disease
82.	Takahiro Niimura, Yoshito Zamami, 川尻雄大, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 基礎研究と臨床研究の融合による薬剤性末梢神経障害に対する予防薬探索, 日本薬学会第141年会, Mar. 2021. (Keyword) data analysis
83.	Takashi Bandoh, Masayuki Chuma, Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Naoto Okada, 泉侑希, 桐野靖, 中村敏己 and Keisuke Ishizawa : 大規模医療情報データベースを活用したバンコマイシン関連腎障害に対する薬剤性腎障害原因薬剤の多剤併用における影響, 日本薬学会第141年会, Mar. 2021. (Keyword) data analysis
84.	Fuka Aizawa, Haruna Kajimoto, Daishi Moriyama, Takahiro Niimura, Yoshito Zamami, Hirofumi Hamano, Mitsuhiro Goda, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : オキサリプラチン誘発末梢神経障害に対するHMG-CoA還元酵素阻害剤の影響, 第262回徳島医学会学術集会, Mar. 2021.
85.	Mitsuhiro Goda, Yoshito Zamami, Takahiro Niimura, 萱野純史, Hirofumi Hamano, Naoto Okada, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, 桐野靖, 中村敏己 and Keisuke Ishizawa : 大規模医療情報データベースを活用した抗がん剤副作用予防のためのリバーストランスレーショナルリサーチ, 日本薬学会第140年会, Mar. 2021.
86.	Yoshika Sakamoto, Yoshito Zamami, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 大規模医療情報データベースを用いたドキソルビシン誘発心筋症に対する予防薬の探索, 日本薬学会第141年会大学院生・学生シンポジウム, Mar. 2021. (Keyword) data analysis

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

リアルワールドデータを活用した薬剤性腎障害に対する新規予防戦略の開発 (Project/Area Number: 23K06234 )
大規模医療情報を用いた薬剤性心筋炎治療薬の探索および有効性の検証 (Project/Area Number: 22K15319 )
Gendered innovation in cancer chemotherapy - real world data driven pharmacological research (Project/Area Number: 22K06863 )
Development of novel drug for drug-induced myocarditis using medical big data and omics data (Project/Area Number: 21K20720 )
Elucidation of the relationship between infectious diseases and aortic diseases by big data analysis and in vivo experiments (Project/Area Number: 21H02646 )
Search by Researcher Number (50910014)

Designated Assistant Professor : Niimura, Takahiro

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Letter:

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)